HealthLynked (HLYK) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 14, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Information [Line Items]
Entity Registrant Name	HealthLynked Corp.
Entity Central Index Key	0001680139
Entity File Number	000-55768
Entity Tax Identification Number	47-1634127
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	1265 Creekside Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Naples
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34108
Entity Phone Fax Numbers [Line Items]
City Area Code	(800)
Local Phone Number	928-7144
Entity Listings [Line Items]
Title of 12(b) Security	None
No Trading Symbol Flag	true
Entity Common Stock, Shares Outstanding		281,947,151

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 172,700	$ 247,222
Accounts receivable, net of allowance for doubtful accounts of $-0- and $-0- as of June 30, 2024 and December 31, 2023, respectively	38,559	20,861
Inventory, net	96,430	133,222
Prepaid expenses and other current assets	34,742	55,210
Contingent sale consideration receivable, current portion	1,663,163	199,645
Total Current Assets	2,005,594	656,160
Property and equipment, net of accumulated depreciation of $580,062 and $521,062 as of June 30, 2024 and December 31, 2023, respectively	234,353	290,755
Intangible assets, net of accumulated amortization of $371,461 and $258,690 as of June 30, 2024 and December 31, 2023, respectively	771,077	883,848
Right of use lease assets	798,593	935,812
Deposits, long term portion	50,047	50,047
Contingent sale consideration receivable, long term portion		1,463,518
Total Assets	3,859,664	4,280,140
Current Liabilities
Accounts payable, accrued expenses and other current liabilities	794,346	614,178
Contract liabilities	284,213	271,774
Lease liability, current portion	363,482	326,033
Notes payable, current portion, net of unamortized original issue discount of $77,613 and $166,487 as of June 30, 2024 and December 31, 2023, respectively	342,743	584,323
Indemnification liability	143,974	143,974
Total Current Liabilities	3,395,688	2,412,024
Long-Term Liabilities
Lease liability, long term portion	438,555	613,386
Government notes payable, long term portion	450,000	450,000
Total Liabilities	4,284,243	3,475,410
Commitments and contingencies (Note 14)
Shareholders’ Equity (Deficit)
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 281,947,151 and 275,964,958 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	28,195	27,597
Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	2,750	2,750
Common stock issuable, $0.0001 par value; 1,977,143 and 2,764,352 as of June 30, 2024 and December 31, 2023, respectively	110,874	281,682
Additional paid-in capital	44,394,892	42,525,837
Accumulated deficit	(44,961,290)	(42,033,136)
Total Shareholders’ Equity (Deficit)	(424,579)	804,730
Total Liabilities and Shareholders’ Equity	3,859,664	4,280,140
Related Party
Current Liabilities
Notes payable and other amounts due to related party, net of unamortized original issue discount of $760,397 and $34,834 as of June 30, 2024 and December 31, 2023, respectively	$ 1,466,930	$ 471,742

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts receivable, net of allowance for doubtful accounts (in Dollars)	$ 0	$ 0
Property and equipment, net of accumulated depreciation (in Dollars)	580,062	521,062
Intangible assets, net of accumulated amortization (in Dollars)	371,461	258,690
net of unamortized original issue discount (in Dollars)	$ 77,613	$ 166,487
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	281,947,151	275,964,958
Common stock, shares outstanding	281,947,151	275,964,958
Common stock issuable, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock issuable, shares	1,977,143	2,764,352
Related Party
net of unamortized original issue discount (in Dollars)	$ 760,397	$ 34,834
Series B convertible preferred stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,750,000	2,750,000
Preferred stock, shares outstanding	2,750,000	2,750,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue
Total revenue	$ 795,078	$ 1,703,496	$ 1,799,310	$ 3,458,650
Operating Expenses and Costs
Practice salaries and benefits	513,891	898,992	1,097,047	1,862,649
Other practice operating expenses	389,222	646,216	871,805	1,270,463
Cost of product revenue	24,723	34,397	55,302	66,457
Selling, general and administrative expenses	861,469	833,689	1,860,912	1,937,437
Depreciation and amortization	85,262	88,293	171,771	176,370
Total Operating Expenses and Costs	1,874,567	2,501,587	4,056,837	5,313,376
Loss from operations	(1,079,489)	(798,091)	(2,257,527)	(1,854,726)
Other Income (Expenses)
Loss on extinguishment of debt	(73,567)	(44,169)	(170,227)	(88,932)
Change in fair value of debt	27,900		27,900
Amortization of original issue discounts on notes payable	(371,356)	(128,689)	(479,621)	(192,049)
Gain from realization of contingent sale consideration receivable		15,000		15,000
Change in fair value of contingent acquisition consideration	635	6,070	711	4,364
Interest expense and other	(44,559)	(39,124)	(49,390)	(50,505)
Total other income (expenses)	(460,947)	(190,912)	(670,627)	(312,122)
Loss from continuing operations before provision for income taxes	(1,540,436)	(989,003)	(2,928,154)	(2,166,848)
Provision for income taxes
Loss from continuing operations	(1,540,436)	(989,003)	(2,928,154)	(2,166,848)
Discontinued operations (Note 4)
Loss from operations of discontinued operations		(14,452)		(58,741)
Gain from disposal of discontinued operations				2,674,069
Gain (loss) on discontinued operations		(14,452)		2,615,328
Net income (loss)	$ (1,540,436)	$ (1,003,455)	$ (2,928,154)	$ 448,480
Loss per share from continuing operations, basic and diluted:
Basic (in Dollars per share)	$ (0.01)	$ 0	$ (0.01)	$ (0.01)
Fully diluted (in Dollars per share)	(0.01)	0	(0.01)	(0.01)
Gain (loss) on discontinued operations, basic and diluted:
Basic (in Dollars per share)	0	0	0	0.01
Fully diluted (in Dollars per share)	0	0	0	0.01
Net loss per share, basic and diluted:
Basic (in Dollars per share)	(0.01)	0	(0.01)	0
Fully diluted (in Dollars per share)	$ (0.01)	$ 0	$ (0.01)	$ 0
Weighted average number of common shares:
Basic (in Shares)	281,788,578	259,817,248	281,136,423	258,481,657
Fully diluted (in Shares)	281,788,578	259,817,248	281,136,423	258,481,657
Patient service revenue, net
Revenue
Total revenue	$ 763,163	$ 1,630,334	$ 1,726,784	$ 3,330,615
Subscription revenue
Revenue
Total revenue	8,166	19,177	15,794	35,476
Product revenue
Revenue
Total revenue	$ 23,749	$ 53,985	$ 56,732	$ 92,559

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Unaudited) - USD ($)	Common Stock	Preferred Stock	Common Stock Issuable	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 25,594	$ 2,750	$ 225,584	$ 41,081,455	$ (41,020,933)	$ 314,450
Balance (in Shares) at Dec. 31, 2022	255,940,389	2,750,000
Sales of common stock	$ 22			18,743		18,765
Sales of common stock (in Shares)	225,000
Other sales of common stock	$ 200			125,998		126,198
Other sales of common stock (in Shares)	2,000,000
Fair value of warrants allocated to proceeds of common stock				73,802		73,802
Fair value of warrants allocated to proceeds of related party debt				95,393		95,393
Consultant and director fees payable with common shares and warrants			54,972			54,972
Shares and options issued to employees	$ 99		(34,200)	67,229		33,128
Shares and options issued to employees (in Shares)	987,500
Net Income (loss)					1,451,935	1,451,935
Balance at Mar. 31, 2023	$ 25,915	$ 2,750	246,356	41,462,620	(39,568,998)	2,168,643
Balance (in Shares) at Mar. 31, 2023	259,152,889	2,750,000
Balance at Dec. 31, 2022	$ 25,594	$ 2,750	225,584	41,081,455	(41,020,933)	314,450
Balance (in Shares) at Dec. 31, 2022	255,940,389	2,750,000
Net Income (loss)						448,480
Balance at Jun. 30, 2023	$ 26,483	$ 2,750	283,592	41,831,448	(40,572,453)	1,571,820
Balance (in Shares) at Jun. 30, 2023	264,829,556	2,750,000
Balance at Mar. 31, 2023	$ 25,915	$ 2,750	246,356	41,462,620	(39,568,998)	2,168,643
Balance (in Shares) at Mar. 31, 2023	259,152,889	2,750,000
Other sales of common stock	$ 542			154,072		154,614
Other sales of common stock (in Shares)	5,416,667
Fair value of warrants allocated to proceeds of common stock				120,386		120,386
Fair value of warrants allocated to proceeds of related party debt				50,025		50,025
Consultant and director fees payable with common shares and warrants	$ 20		37,236	15,380		52,636
Consultant and director fees payable with common shares and warrants (in Shares)	200,000
Shares and options issued to employees	$ 6			24,607		24,613
Shares and options issued to employees (in Shares)	60,000
Incremental fair value of repriced warrants				4,358		4,358
Net Income (loss)					(1,003,455)	(1,003,455)
Balance at Jun. 30, 2023	$ 26,483	$ 2,750	283,592	41,831,448	(40,572,453)	1,571,820
Balance (in Shares) at Jun. 30, 2023	264,829,556	2,750,000
Balance at Dec. 31, 2023	$ 27,597	$ 2,750	281,682	42,525,837	(42,033,136)	804,730
Balance (in Shares) at Dec. 31, 2023	275,964,958	2,750,000
Sales of common stock	$ 510			255,413		255,923
Sales of common stock (in Shares)	5,100,000
Fair value of warrants allocated to proceeds of common stock				99,077		99,077
Fair value of warrants allocated to proceeds of related party debt				209,943		209,943
Fair value of beneficial conversion feature allocated to proceeds of related party debt				146,405		146,405
Consultant and director fees payable with common shares and warrants			43,437			43,437
Shares and options issued to employees			(270,549)	320,246		49,697
Net Income (loss)					(1,387,718)	(1,387,718)
Balance at Mar. 31, 2024	$ 28,107	$ 2,750	54,570	43,556,921	(43,420,854)	221,494
Balance (in Shares) at Mar. 31, 2024	281,064,958	2,750,000
Balance at Dec. 31, 2023	$ 27,597	$ 2,750	281,682	42,525,837	(42,033,136)	804,730
Balance (in Shares) at Dec. 31, 2023	275,964,958	2,750,000
Net Income (loss)						(2,928,154)
Balance at Jun. 30, 2024	$ 28,195	$ 2,750	110,874	44,394,892	(44,961,290)	(424,579)
Balance (in Shares) at Jun. 30, 2024	281,947,151	2,750,000
Balance at Mar. 31, 2024	$ 28,107	$ 2,750	54,570	43,556,921	(43,420,854)	221,494
Balance (in Shares) at Mar. 31, 2024	281,064,958	2,750,000
Sales of common stock	$ 87			38,734		38,821
Sales of common stock (in Shares)	877,193
Fair value of warrants allocated to proceeds of common stock				11,178		11,178
Fair value of warrants allocated to proceeds of related party debt				364,422		364,422
Fair value of beneficial conversion feature allocated to proceeds of related party debt				392,905		392,905
Consultant and director fees payable with common shares and warrants			69,624			69,624
Shares and options issued to employees	$ 1		(13,320)	30,732		17,413
Shares and options issued to employees (in Shares)	5,000
Net Income (loss)					(1,540,436)	(1,540,436)
Balance at Jun. 30, 2024	$ 28,195	$ 2,750	$ 110,874	$ 44,394,892	$ (44,961,290)	$ (424,579)
Balance (in Shares) at Jun. 30, 2024	281,947,151	2,750,000

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities
Net income (loss)	$ (2,928,154)	$ 448,480
Loss from discontinued operations		58,741
Adjustments to reconcile net loss to net cash used in operating activities:
Gain from disposal of discontinued operations		(2,674,069)
Depreciation and amortization	171,771	176,370
Stock based compensation, including amortization of deferred equity compensation	180,168	169,707
Amortization of debt discount	479,621	192,049
Loss on extinguishment of debt	170,227	88,932
Change in fair value of debt	(27,900)
Gain from realization of contingent sale consideration receivable		(15,000)
Change in fair value of contingent acquisition consideration	(711)	(4,364)
Changes in operating assets and liabilities:
Accounts receivable	(17,698)	11,084
Inventory	36,792	36,375
Prepaid expenses and other current assets	20,468	144,354
Right of use lease assets	165,264	409,222
Accounts payable and accrued expenses	189,591	(122,776)
Lease liability	(165,427)	(408,440)
Contract liabilities	12,439	(164,359)
Net cash used in continuing operating activities	(1,713,549)	(1,653,694)
Net cash used in discontinued operating activities		(49,561)
Net cash used in operating activities	(1,713,549)	(1,703,255)
Cash Flows from Investing Activities
Proceeds from sale of discontinued operations		1,961,381
Acquisition of property and equipment	(2,598)
Net cash provided by (used in) continuing investing activities	(2,598)	1,961,381
Net cash used in discontinued investing activities
Net cash provided by (used in) investing activities	(2,598)	1,961,381
Cash Flows from Financing Activities
Proceeds from sale of common stock	405,000	475,000
Proceeds from related party notes payable	1,650,000	645,000
Proceeds from third party notes payable	135,000	408,500
Repayment of related party notes payable	(37,602)	(555,597)
Repayment of third party notes payable	(510,773)	(373,948)
Net cash provided by continuing financing activities	1,641,625	598,955
Net cash provided by discontinued financing activities
Net cash provided by financing activities	1,641,625	598,955
Net increase (decrease) in cash	(74,522)	857,081
Cash, beginning of period	247,222	61,891
Cash, end of period	172,700	918,972
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	13,158	14,587
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Recognition of operating lease: right of use asset and lease liability	28,044	30,468
Common stock issuable issued during period		34,105
Fair value of options issued in satisfaction of common stock issuable	283,869
Fair value of warrants allocated to proceeds of related party notes payable	552,848	95,393
Fair value of beneficial conversion feature allocated to proceeds of related party notes payable	539,310
Fair value of warrants issued to extend debt	21,518	50,025
Incremental fair value of convertible note payable to related party resulting from refinancing	88,127
Net carrying value of equity liabilities (assets) written off		4,647
Proceeds from sale of common stock under Standby Equity Purchase Agreement applied to note payable balance		18,743
Accrued interest included in fair value of note payable	$ 8,712

Business and Business Presentat

Business and Business Presentation	6 Months Ended
	Jun. 30, 2024
Business and Business Presentation [Abstract]
BUSINESS AND BUSINESS PRESENTATION	NOTE 1 – BUSINESS AND BUSINESS PRESENTATION HealthLynked Corp. (the “Company”) was incorporated in the State of Nevada on August 4, 2014. On September 2, 2014, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada setting the total number of authorized shares at 250,000,000 shares, which included up to 230,000,000 shares of common stock and 20,000,000 shares of “blank check” preferred stock. On February 5, 2018, the Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares. The Company currently operates in three distinct divisions: ● Health Services Division ● Digital Healthcare Division ● Medical Distribution Division In a strategic restructuring, during October 2022, our Board of Directors (the “Board”) approved the divestiture of the former ACO/MSO Division, including Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”). CHM and AHP were involved in enhancing coordinated care through the Medicare Shared Savings Program (“MSSP”). The divestiture was completed on January 17, 2023, aligning with the Company’s focus on core growth areas. See Note 4, “Discontinued Operations,” for additional information. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2023 and 2022, respectively, which are included in the Company’s Form 10-K, filed with the United States Securities and Exchange Commission (the “Commission”) on April 1, 2024. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results for the entire year ending December 31, 2024. On a consolidated basis, the Company’s operations are comprised of the parent company, HealthLynked Corp., and its five subsidiaries: NWC, NCFM, BTG, MOD and AEU. Results through January 17, 2023 also include operations of AHP, which was sold, and CHM, which was discontinued, both effective as of January 17, 2023. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation. Uncertainty Due to Geopolitical Events Due to the Hamas-Israel and Russia-Ukraine conflicts, there has been uncertainty and disruption in the global economy. Although these events did not have a direct material adverse impact on the Company’s financial results for the three or six months ended June 30, 2024, at this time the Company is unable to fully assess the aggregate impact the Hamas-Israel and Russia-Ukraine conflicts will have on its business due to various uncertainties, which include, but are not limited to, the duration of the conflicts, the conflicts’ effect on the economy, the impact on the Company’s businesses and actions that may be taken by governmental authorities related to the conflicts.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying condensed consolidated financial statements follows: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets. Revenue Recognition Patient service revenue Patient service revenue is earned for patient services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time includes revenue from NCFM annual access contracts (the Medical Membership and Concierge Program prior to October 1, 2023 and the more comprehensive Optimal Health 365 Access Plan thereafter), NWC annual administration fees, and BTG physical therapy bundles. Revenue from NCFM Medical Memberships and Concierge contracts and NWC annual administration fees, which include bundled products and services that have substantially the same pattern of transfer to the customer, is recognized over the period of delivery, which is the same as the period of the contract (typically, one year). Revenue from prepaid BTG physical therapy bundles, for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual visits incurred in relation to total expected visits. At inception of such contracts, the Company recognizes contract liabilities for the value of services to be provided and, where applicable, contract assets for recoverable amounts incurred to obtain a customer contract that would not have incurred if the contract had not been obtained. The Company believes that these methods provide a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than NCFM annual access contracts, NWC annual administration fees, and BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient. Patient service revenues are presented on the statement of operations net of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the six months ended June 30, 2024 or 2023 to the judgments applied in determining the amount and timing of patient service revenue. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates; ● Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member. ● Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and for those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers. Product and Other Revenue Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue are recognized when payment is received but for which the Company has not met its product fulfillment performance obligation. Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States. The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products. Cash and Cash Equivalents For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $-0- and $-0- in cash balances in excess of the FDIC insured limit as of June 30, 2024 and December 31, 2023, respectively. Accounts Receivable Trade receivables related to NWC services billed to third party payors are carried at the estimated collectible amount, which is the standard charge based on the Company’ list price, net of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 61% of total gross billings. Trade accounts receivable are recorded at this net amount. As of June 30, 2024 and December 31, 2023, the Company’s gross patient services accounts receivable were $63,733 and $34,481, respectively, and net patient services accounts receivable were $38,559 and $20,861, respectively, based upon net reporting of accounts receivable. As of June 30, 2024 and December 31, 2023, the Company’s allowance for doubtful accounts was $-0- and $-0-, respectively. Other Comprehensive Income The Company does not have any activity that results in Other Comprehensive Income. Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein. Inventory Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold. Intangible Assets The Company recognizes an acquired intangible whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities; ● Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data; ● Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability. The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments. Stock-Based Compensation The Company accounts for stock-based compensation to employees and nonemployees under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the six months ended June 30, 2024 since the Company sustained a loss in that period. No income tax was provided for the six months ended June 30, 2023 because the Company had sufficient operating loss carryforwards to offset any net income for the full year 2023, including income from capital gains related to the disposal of discontinued operations. The Company recognized net loss for the full year 2023. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable. Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, accounts payable, and accrued liabilities approximated their fair value. Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the six months ended June 30, 2024 and 2023, the Company reported a loss from continuing operations. As a result, diluted net income (loss) per common share is computed in the same manner as basic net income (loss) per common share, even though the Company had net income in the six months ended June 30, 2023 after adjusting for discontinued operations. The Company excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of June 30, 2024 and December 31, 2023, potentially dilutive securities were comprised of (i) 96,064,592 and 77,414,648 warrants outstanding, respectively, (ii) 9,448,730 and 5,093,738 stock options outstanding, respectively, (iii) 613,160 and 1,484,488 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,977,143 and 2,764,352 common shares issuable that are earned but not paid under consulting and director compensation arrangements, (v) up to 36,972,139 and 3,780,000 shares potentially issuable upon conversion of outstanding fixed price convertible notes payable, and (vi) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred. Common Stock Awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has three operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices). The Company’s ACO/MSO segment was sold on January 17, 2023. As described in further detail in Note 4, “Discontinued Operations,” this unit’s assets and liabilities are classified as held for sale as of December 31, 2022 and the unit’s results of operations are classified as “Income (loss) from operations of discontinued operations” in the three and six months ended June 30, 2024 and 2023. Recently Adopted Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments.” The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company adopted this standard for the year ended December 31, 2023. The adoption did not have a material effect on the Company’s consolidated financial statements. In October 2021, the FASB issued guidance which requires companies to apply Topic 606, Revenue from Contracts with Customers In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the six months ended June 30, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the six months ended June 30, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

Liquidity and Going Concern Ana

Liquidity and Going Concern Analysis	6 Months Ended
	Jun. 30, 2024
Liquidity and Going Concern Analysis [Abstract]
LIQUIDITY AND GOING CONCERN ANALYSIS	NOTE 3 – LIQUIDITY AND GOING CONCERN ANALYSIS Under ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. Pursuant to ASU 2014-15, in evaluating the Company’s ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the Company’s financial statements were issued (August 14, 2025). Management considered the Company’s current financial condition and liquidity sources, including current funds available, forecasted future cash flows and the Company’s obligations due before August 14, 2025. The Company is subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from its Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s cost structure. As of June 30, 2024, the Company had cash balances of $172,700, a working capital deficit of $1,390,094 and an accumulated deficit of $44,961,290. For the six months ended June 30, 2024, the Company had a net loss of $2,928,154 and used cash from operating activities of $1,713,549. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months. Management has evaluated the significance of the conditions described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were issued. As described further in Note 4, “Discontinued Operations,” on January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP. The Company received $750,000 upon signing of the AHP Merger Agreement, the $31,381 Stub Period Reimbursement (defined below) in March 2023, $1,750,000 ($1,540,000 net after commissions) during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, and $1,873,993 ($1,186,231 net after commissions and other expenses) related to AHP’s Plan Year 2022 MSSP shared savings. The Company may also receive future proceeds under the AHP Merger Agreement comprised of (i) up to $500,000 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings to reimburse amounts advanced to participating physicians at signing that would be received in October 2024, and (ii) proceeds from sale of shares of the Buyer’s common stock if the Buyer completes an initial public offering by February 1, 2025. During the six months ended June 30, 2024, the Company also (i) received net proceeds from the issuance of notes payable to related parties and third parties totaling $1,785,000 and made repayments on existing and new notes payable to related parties and third parties totaling $548,375, and (ii) received $405,000 proceeds from the sale of its common stock. On July 5, 2022, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”) (See Note 13, “Shareholders’ Equity,” below for additional information on the SEPA). Pursuant to the SEPA, the Company shall have the right to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by the Company to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of the Company’s common stock during the applicable pricing period, the Company cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds to be raised by the Company from those sales, if any. During the six months ended June 30, 2023, the Company sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. The Company has not made any draws pursuant to the SEPA since January 2023. Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through August 14, 2025. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2024
Discontinued Operations [Abstract]
DISCONTINUED OPERATIONS	NOTE 4 – DISCONTINUED OPERATIONS Description of Transaction During the fourth quarter of 2022, the Board approved a plan to sell the Company’s ACO/MSO Division, which operated an Accountable Care Organization (“ACO”) that assisted physician practices in providing coordinated and more efficient care to patients via the MSSP, which rewards providers for efficiency in patient care. On January 17, 2023, the Company entered into an Agreement and Plan of Merger (the “AHP Merger Agreement”), pursuant to which the buyer PBACO Holding, LLC, an operator of ACOs, (the “Buyer”) agreed to buy, and the Company agreed to sell, AHP (the “AHP Sale”). Pursuant to the terms of the AHP Merger Agreement, the Company received or will receive the following consideration: (1) $750,000 in cash paid upon signing of the definitive agreement (received January 18, 2023) (the “Upfront Cash Consideration”); (2) the Buyer shall reimburse the Company for expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023 (the “Stub Period Reimbursement”)($31,381 paid in March 2023); (3) up to $1,750,000 net incremental cash based on the agreement to participate in Buyer’s ACO by AHP’s existing physician practices or newly added practices, scaled based on the number of covered patients transferred to PBACO by July 31, 2023 (the “Incremental Cash Consideration”), of which $1,225,000 ($1,180,000 net after commissions) was received in June 2023 and $150,000 ($120,000 net after commissions) was received in July 2023; (4) net proceeds, including allocation for expenses, from any MSSP Shared Savings related to AHP’s plan year 2022 (the “2022 MSSP Consideration”), of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in October 2023; (5) $500,000 of the Incremental Cash Consideration will be allocated to AHP’s participating physicians upon receipt and will be reimbursed to HealthLynked by the Buyer in 2024 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings (the “Physician Advance Consideration”); and (6) in the event that Buyer completes a planned initial public offering (“IPO”) by February 1, 2025, shares in the public entity at the time of the IPO with a value equal to AHP’s 2021 earnings before interest, taxes depreciation and amortization (“EBITDA”) times the multiple of EBITDA used to value the public entity’s IPO shares, net of any cash consideration previously paid by the Buyer and subject to vesting requirements detailed in the AHP Merger Agreement (the “IPO Share Consideration”). The Company is also required to indemnify the Buyer against liabilities arising from Buyer’s operation of AHP prior to the Buyer’s IPO date, less a deductible equal to 1% of the aggregate merger consideration (the “Indemnification Clause”). In the event Buyer goes public through means other than an IPO, the parties agreed to modify the terms of the IPO Share Consideration to implement such alternate structure. In the event Buyer does not go public by IPO or other means by February 1, 2025, the Company receives no IPO Share Consideration, and the Transaction consideration is capped at the cash consideration of up to $3,000,000 plus the MSSP Consideration. Any participating physician advances will be repaid to the Company out of AHP’s 2023 performance year MSSP Shared Savings, which would be received in 2024. Pursuant to the terms of the Merger Agreement, formal transfer of the equity ownership of AHP from the Company to the Buyer will occur at the earlier of (i) Buyer’s IPO, (ii) Buyer going public by other means, or (iii) if Buyer does not go public, on February 1, 2025. Until that time, the Company has the right, but not the obligation, to reacquire AHP for a price equal to any consideration already paid by the Buyer for AHP, plus all expenses incurred by Buyer in operating AHP after January 16, 2023. Concurrent with the AHP Merger Agreement, AHP and the Buyer also entered into a Management Services Agreement (the “MSA”), pursuant to which the Buyer assumed full control of managing AHP’s business operations and paying AHP’s operating expenses after January 16, 2023. The term of the MSA is from January 17, 2023 to August 1, 2024, which is the latest date that equity ownership of AHP can transfer from the Company to the Buyer. The Buyer agreed in the Merger Agreement to reimburse the Company for reasonable expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023, which we refer to as the Stub Period Reimbursement, during which time the Company had operational and financial control of AHP and CHM. Concurrent with the AHP Merger Agreement and the MSA, and as a result of the Buyer assuming control and responsibility of AHP’s operations, the Company discontinued its operations of CHM. Discontinued Operations The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. No assets or liabilities were classified as held for sale as of June 30, 2024 or December 31, 2023. The financial results of the ACO/MSO Division are presented as income (loss) from discontinued operations, net of income taxes on our consolidated statement of operations. The following table presents financial results of the ACO/MSO Division for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended 2024 2023 2024 2023 Revenue: Consulting revenue $ — $ — $ — $ 23,646 Total revenue — — — 23,646 Operating Expenses and Costs: Medicare shared savings expenses — 14,452 — 82,387 Loss from operations of discontinued operations before income taxes — (14,452 ) — (58,741 ) Provision for income taxes — — — — Loss from discontinued operations, net of income taxes $ — $ (14,452 ) $ — $ (58,741 ) Net cash used in operations of the ACO/MSO Division was $ -0- Derecognition and Gain from Disposal of Discontinued Operations As a result of the AHP Sale and pursuant to the terms and conditions of the AHP Merger Agreement and the MSA, the Company ceased to have a controlling financial interest in AHP as of January 17, 2023. Accordingly, in connection with the transaction, the Company deconsolidated AHP as of January 17, 2023. In connection with the deconsolidation, the Company recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized. The Company elected to record the contingent portion of consideration receivable at fair value on the sale date pursuant to the guidance in FASB Emerging Issues Task Force Issue 09-4, “Seller Accounting for Contingent Consideration,” (“EITF 09-4”). The fair value of consideration received and receivable is shown in the following table: Upfront Cash Consideration paid at signing $ 750,000 Incremental Cash Consideration 1,311,567 IPO Share Consideration 1,463,517 2022 MSSP Consideration 312,987 Physician Advance Consideration 199,645 Stub Period Reimbursement 31,381 Total fair value of contingent consideration receivable 3,319,097 Total fair value of consideration received and receivable $ 4,069,097 The fair value of contingent consideration receivable was determined using an expected present value approach, which applies a discount rate to a probability-weighted stream of net cash flows based on multiple scenarios, as estimated by management. As such, the fair values of contingent consideration receivable rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the fair valuation. Significant assumptions related to the valuation of contingent consideration receivable include the likelihood of a Buyer IPO, the valuation of the Buyer’s common stock in a potential IPO, the likelihood that AHP would meet its performance benchmarks to the extent that it will receive shared savings for plan year 2022, the likelihood that AHP under the management of the Buyer would receive sufficient shared savings in plan years 2023 and/or 2024 to pay the Physician Advance Consideration, and the likelihood that the Company would be able to transfer or add new participating physicians to AHP before July 31, 2023 in order to collect the Incremental Cash Consideration. The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows: Prepaid expenses $ 1,500 Intangible asset - ACO physician contract 1,073,000 Goodwill 381,856 Contract liability (20,278 ) Contingent acquisition consideration (185,024 ) Net Book Value of Assets and Liabilities Sold $ 1,251,054 Prepaid expenses are prepaid services from which the Buyer will benefit following the AHP Sale. Intangible assets and goodwill represent the carrying value of assets recorded at the time the Company acquired CHM and AHP in 2020 (the “Original Acquisition”). Contract liability represents remaining unearned revenue for which the Buyer is required to provide the performance obligations after January 17, 2023. In connection with the AHP Sale, the remaining value of contingent acquisition consideration (“CAC”) related to the Original Acquisition was written off. After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the six months ended June 30, 2023 as follows: Total fair value of consideration received and receivable $ 4,069,097 Less: net book value of assets and liabilities sold (1,251,054 ) Less: fair value of Indemnification Clause (143,974 ) Gain from disposal of discontinued operations $ 2,674,069 After January 17, 2023, and as prescribed under EITF 09-4, the Company has elected to subsequently treat the contingent consideration receivable using gain contingency guidance and only record a gain or loss when the contingency is resolved. Accordingly, the Company does not prospectively remeasure the fair value of contingent consideration receivable each reporting period. Receipts of Contingent Sale Consideration Receivable The Company received $750,000 upon signing of the AHP Merger Agreement, the $31,381 Stub Period Reimbursement in March 2023, $1,750,000 ($1,540,000 net after commissions) Incremental Cash Consideration during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, and $1,873,993 ($1,186,231 net after commissions and other expenses) in October 2023 related to AHP’s Plan Year 2022 MSSP shared savings. The carrying value of the remaining unresolved components of contingent consideration receivable as of June 30, 2024 and December 31, 2023 was as follows: IPO Share Consideration $ 1,463,518 Physician Advance Consideration 199,645 Remaining contingent sale consideration receivable $ 1,663,163

Prepaid Expenses and Other

Prepaid Expenses and Other	6 Months Ended
	Jun. 30, 2024
Prepaid Expenses and Other [Abstract]
PREPAID EXPENSES AND OTHER	NOTE 5 – PREPAID EXPENSES AND OTHER Prepaid and other expenses as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Insurance prepayments $ 8,099 $ 11,209 Other expense prepayments 18,379 38,391 Rent deposits 50,047 50,547 Contract assets 8,264 5,110 Total prepaid expenses and other 84,789 105,257 Less: long term portion (50,047 ) (50,047 ) Prepaid expenses and other, current portion $ 34,742 $ 55,210 Contract assets relate to amounts incurred to obtain a customer contract that would not have been incurred if the contract had not been obtained, such as commissions, associated with NCFM annual access contracts.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2024
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Medical equipment $ 496,452 $ 493,854 Furniture, office equipment and leasehold improvements 317,963 317,963 Total property and equipment 814,415 811,817 Less: accumulated depreciation (580,062 ) (521,062 ) Property and equipment, net $ 234,353 $ 290,755 Depreciation expense was $29,531 and $31,253, during the three months ended June 30, 2024 and 2023, respectively, and $59,000 and $62,290 during the six months ended June 30, 2024 and 2023, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2024
Intangible Assets [Abstract]
INTANGIBLE ASSETS	NOTE 7 – INTANGIBLE ASSETS Identifiable intangible assets as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 NCFM: Medical database $ 1,101,538 $ 1,101,538 NCFM: Website 41,000 41,000 Total intangible assets 1,142,538 1,142,538 Less: accumulated amortization (371,461 ) (258,690 ) Intangible assets, net $ 771,077 $ 883,848 Intangible assets arose from the acquisition of NCFM in April 2019. The NCFM medical database is being prospectively amortized starting January 1, 2023 over an estimated five-year useful life. The NCFM website began being amortized over a five-year life from the acquisition date. Amortization expense related to intangible assets was $55,731 and $57,040, during the three months ended June 30, 2024 and 2023, respectively, and $112,771 and $114,080 during the six months ended June 30, 2024 and 2023, respectively. Future amortization expense of intangible assets is expected to be as follows: 2024 (July to December) $ 110,154 2025 220,308 2026 220,308 2027 220,307 Thereafter — Total future amortization expense $ 771,077

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
LEASES	NOTE 8 – LEASES The Company has separate operating leases, and related amendments thereto, for office space related to its NWC, NCFM, BTG and AEU practices, its corporate headquarters, and a copier lease that expire in July 2026, May 2025, March 2025, March 2026, November 2026, and January 2027, respectively. As of June 30, 2024, the Company’s weighted-average remaining lease term relating to its operating leases was 2.2 years, with a weighted-average discount rate of 22.79%. The table below summarizes the Company’s lease-related assets and liabilities as of June 30, 2024 and December 31, 2023: June 30, December 31, 2024 2023 Lease assets $ 798,593 $ 935,812 Lease liabilities Lease liabilities (short term) $ 363,482 $ 326,033 Lease liabilities (long term) 438,555 613,386 Total lease liabilities $ 802,037 $ 939,419 Lease expense was $129,968 and $120,501, during the three months ended June 30, 2024 and 2023, respectively, and $259,399 and $227,297 during the six months ended June 30, 2024 and 2023, respectively. Maturities of operating lease liabilities were as follows as of June 30, 2024: 2024 (July to December) $ 279,478 2025 477,584 2026 335,634 2027 990 Total lease payments 1,093,686 Less interest (291,649 ) Present value of lease liabilities $ 802,037

Accounts Payable, Accrued Expen

Accounts Payable, Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2024
Accounts Payable, Accrued Expenses and Other Current Liabilities [Abstract]
ACCOUNTS PAYABLE, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 9 – ACCOUNTS PAYABLE, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Amounts related to accounts payable, accrued expenses and other current liabilities as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Trade accounts payable $ 527,645 $ 251,479 Accrued payroll liabilities 99,282 110,103 Accrued operating expenses 73,007 91,238 Accrued interest 65,579 57,074 Accrued commissions payable from 2022 MSSP Consideration 25,000 100,000 Contingent acquisition consideration payable 1,479 2,189 Product return allowance 2,354 2,095 $ 794,346 $ 614,178

Contract Liabilities

Contract Liabilities	6 Months Ended
	Jun. 30, 2024
Contract Liabilities [Abstract]
CONTRACT LIABILITIES	NOTE 10 – CONTRACT LIABILITIES Amounts related to contract liabilities as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Patient services paid but not provided - NCFM $ 144,966 $ 95,334 Patient services paid but not provided - BTG 88,256 100,857 Patient services paid but not provided - NWC 50,029 75,438 Unshipped products - MOD 962 145 $ 284,213 $ 271,774 Contract liabilities relate to (i) NCFM annual access contracts, including Medical Membership, Concierge Service and Optimal Health 365 Access Plan contracts pursuant to which patients prepay for access to services to be provided at the patient’s request over a period of time, (ii) BTG contracts pursuant to which patients prepay for access to a fixed number of visits used at the patients’ discretion, (iii) NWC annual administration fees, and (iv) MOD sold but unshipped products.

Amounts Due to Related Party an

Amounts Due to Related Party and Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Amounts Due to Related Party and Related Party Transactions [Abstract]
AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS	NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS Amounts due to related parties as of June 30, 2024 and December 31, 2023 were comprised of the following: June 30, December 31, 2024 2023 Note Payable to Dr. Michael Dent, March 2023 $ — $ 12,601 Note Payable to Dr. Michael Dent, June 2023 — 26,875 Note Payable to Dr. Michael Dent, December 2023 — 166,500 Convertible Note Payable I to Dr. Michael Dent, March 2024 150,000 — Convertible Note Payable II to Dr. Michael Dent, March 2024 ** 392,733 — Convertible Note Payable III to Dr. Michael Dent, March 2024 ** 183,994 — Convertible Note Payable IV to Dr. Michael Dent, April 2024 150,000 — Convertible Note Payable V to Dr. Michael Dent, April 2024 50,000 — Convertible Note Payable VI to Dr. Michael Dent, June 2024 1,000,000 — Face value of notes payable to related party 1,926,727 205,976 Less: unamortized discounts (760,397 ) (34,834 ) Notes payable to related party, total 1,166,330 171,142 Plus deferred compensation payable to Dr. Michael Dent 300,600 300,600 Total due to related party $ 1,466,930 $ 471,742 ** - denotes note payable carried at fair value Notes Payable to Dr. Michael Dent On November 8, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $150,000 (the “November MCA”). The Company was required to repay the November MCA at the rate of $3,750 per week until the balance of $195,000 was repaid, which was scheduled for November 2023. At inception, the Company recognized a note payable in the amount of $195,000 and a discount against the note payable of $45,000. The discount was being amortized over the life of the November MCA. The Company made payments totaling $-0- and $67,500 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $101,250 in the six months ended June 30, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $11,219 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $22,438 in the six months ended June 30, 2024 and 2023, respectively. The November MCA was repaid in full during the fourth quarter of 2023. As of June 30, 2024 and December 31, 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively. On December 13, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $110,000 (the “December MCA”). The Company was required to repay the December MCA at the rate of $2,750 per week until the balance of $143,000 was repaid, which was scheduled for December 2023. In connection with the December MCA, the Company issued 3,142,857 three-year warrants to the holder with an exercise price of $0.035. The fair value of the warrants was $63,420. At inception, the Company recognized a note payable in the amount of $143,000 and a discount against the note payable of $68,281 for the allocated fair value of the original issue discounts and warrants. The discount was being amortized over the life of the December MCA. The Company made payments totaling $-0- and $49,500 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $74,250 in the six months ended June 30, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $17,071 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $34,141 in the six months ended June 30, 2024 and 2023, respectively. The December MCA was repaid in full during the fourth quarter of 2023. As of June 30, 2024 and December 31, 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively. On January 5, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $10,000 (the “$10k Dent Note”). The $10k Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the $10k Dent Note, the Company issued 96,154 five-year warrants to the holder with an exercise price of $0.104. The fair value of the warrants was $6,843. At inception, the Company recognized a note payable in the amount of $10,000 and a discount against the note payable of $3,851 for the allocated fair value of the warrants. The discount was to be amortized over the life of the $10k Dent Note. The $10k Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $269 and $53, respectively, in the three and six months ended June 30, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $-0- and $3,582 in the three and six months ended June 30, 2023, respectively. On January 13, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $161,000 (the “January 2023 Dent Note”). Net proceeds were $160,000, taking into account the original issue discount of $1,000. The January 2023 Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the January 2023 Dent Note, the Company issued 860,215 three-year warrants to Dr. Dent with an exercise price of $0.093. The fair value of the warrants was $56,123. At inception, the Company recognized a note payable in the amount of $161,000 and a discount against the note payable of $42,553 for the allocated fair value of the original issue discount and warrants. The discount was to be amortized over the life of the January 2023 Dent Note. The January 2023 Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $1,373 and $397, respectively, in the six months ended June 30, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $41,181 in the six months ended June 30, 2023. On February 14, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $186,000 (the “February 2023 Dent Note”). Net proceeds were $185,000 after an original issue discount of $1,000. The February 2023 Dent Note bore interest at a rate of 15% per annum and matured six months from issuance. In connection with the February 2023 Dent Note, the Company issued 685,185 three-year warrants to Dr. Dent with an exercise price of $0.135. The fair value of the warrants was $66,136. At inception, the Company recognized a note payable in the amount of $186,000 and a discount against the note payable of $50,989 for the allocated fair value of the original issue discounts and warrants. The discount was amortized over the life of the February 2023 Dent Note. The February 2023 Dent Note was repaid in full during August 2023. No payments were made on the February 2023 Dent Note in the three or six months ended June 30, 2024 or 2023. Amortization of debt discount was $-0- and $25,494 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $38,241 in the six months ended June 30, 2024 and 2023. On March 14, 2023, the Company issued a promissory note payable to a trust controlled by Dr. Dent with a stated principal amount of $112,510 and prepaid interest of $13,501 for total scheduled repayments of $126,011 (the “March 2023 Dent Note”). The March 2023 Dent Note had an original issue discount of $12,510, resulting in net proceeds to the Company of $100,000. At inception, the Company recognized a note payable in the amount of $126,011 and a discount against the note payable of $26,011. The March 2023 Dent Note did not bear interest in excess of the prepaid interest and original issue discount and matured on March 14, 2024. The Company was required to make 10 monthly payments of $12,601 starting April 30, 2023. At inception, the Company recorded a discount against the note of $26,011, representing the difference between the total required repayments and the net proceeds received, which was amortized over the repayment period. The March 2023 Dent Note gave the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. The Company made payments totaling $-0- and $25,202 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $25,202 in the six months ended June 30, 2024 and 2023. Amortization of debt discount was $2,504 and $7,351 in the three months ended June 30, 2024 and 2023, respectively, and $2,504 and $8,643 in the six months ended June 30, 2024 and 2023 respectively. The March 2023 Dent Note was repaid in January 2024. On April 13, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $100,000 (the “April 2023 Dent Note”). Net proceeds were $100,000. The April 2023 Dent Note bore a fixed interest charge of $15,000 (15% per annum) and had an original maturity date of May 12, 2023. At inception, the Company recorded a discount against the note of $15,000, representing the difference between the total required repayments and the net proceeds received. Amortization of the debt discount was $15,000 in the three and six months ended June 30, 2023. On May 12, 2023, the Company issued 654,450 five-year warrants with an exercise price of $0.0764 to Dr. Michael Dent in exchange for extending the maturity date of the April 2023 Dent Note until June 30, 2023. The April 2023 Dent Note was repaid in full on June 29, 2023. In connection with the extension and repayment, the Company recognized a loss on extinguishment of debt of $31,621 in the three and six months ended June 30, 2023. On April 27, 2023, the Company issued an unsecured promissory note to George O’Leary, its Chief Financial Officer, with a face value of $35,000 (the “April 2023 O’Leary Note”). Net proceeds were $35,000. The April 2023 O’Leary Note bore a fixed interest charge of $5,250 (15% per annum) and was scheduled to mature May 25, 2023. At inception, the Company recorded a discount against the note of $5,250, representing the difference between the total required repayments and the net proceeds received. Amortization of the debt discount was $5,250 in the three and six months ended June 30, 2023. On June 2, 2023, the Company issued 261,194 five-year warrants with an exercise price of $0.067 to Mr. O’Leary in exchange for extending the maturity date of the April 2023 O’Leary Note until July 13, 2023. The April 2023 O’Leary Note was repaid in full on June 15, 2023. In connection with the extension and repayment, the Company recognized a loss on extinguishment of debt of $12,549 in the three and six months ended June 30, 2023. On June 8, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $30,000 (the “June 2023 Dent Note I”). Net proceeds were $30,000. The June 2023 Dent Note I bore a fixed interest charge of $4,500 (15% per annum) and had an original maturity date of June 30, 2023. At inception, the Company recorded a discount against the note of $4,500, representing the difference between the total required repayments and the net proceeds received. Amortization of the debt discount was $4,500 in the three and six months ended June 30, 2023. The June 2023 Dent Note was repaid in full on June 29, 2023. On June 26, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $25,000 (the “June 2023 Dent Note II”). The June 2023 Dent Note II bore a fixed interest charge of $1,875 (15% per annum) and matured on December 26, 2023. At inception, the Company recorded a note payable in the amount of $26,875 and a discount against the note of $1,875. Amortization of debt discount was $-0- and $41 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $41 in the six months ended June 30, 2024 and 2023, respectively. The June 2023 Dent Note was repaid in full in January 2024. On December 1, 2023, the Company issued an unsecured promissory note to a trust controlled by Dr. Dent with a face value of $150,000 (the “December 2023 Dent Note”). The December 2023 Dent Note bore a fixed interest charge of $15,000 (10% per annum) and $1,500 in fixed fees and matured on February 28, 2024. The Company received net proceeds of $150,000. In connection with the note, the Company issued 1,500,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $32,269. At inception, the Company recorded a note payable in the amount of $166,500 and a discount against the note payable of $48,769 for the allocated fair value of the original issue discount and warrants. The Company made no payments in the three or six months ended June 30, 2024 or 2023. Amortization of debt discount was $-0- and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $32,330 and $-0- in the six months ended June 30, 2024 and 2023, respectively. On March 27, 2024, the December 2023 Dent Note was refinanced and replaced with the March 2024 Dent Note III as described below. No loss on extinguishment of debt was recognized in the six months ended June 30, 2024 because the discount was fully amortized at the time of the refinancing. On March 27, 2024, the Company issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024 (the “March 2024 Dent Note I”), (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of August 24, 2024 (the “March 2024 Dent Note II”), and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (the “March 2024 Dent Note III”, and collectively, the “March 2024 Dent Notes”). The full amount of principal and accrued interest on each of the March 2024 Dent Notes is due at the respective maturity date of each note. Each of the March 2024 Dent Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0573 per share. In connection with the issuance of the March 2024 Dent Notes, the Company also issued to the holder a ten-year warrant to purchase 6,660,000 shares of the Company’s common stock at an exercise price of $0.06 per share (the “March 2024 Warrant”). The fair value of the March 2024 Warrant was $254,345. Net proceeds from the March 2024 Dent Note I were $350,000. At inception, the Company recorded a discount of $203,588, representing the allocated fair value of the beneficial conversion feature (“BCF”) and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note I. The discount was being amortized over the original life of the note. Amortization of debt discount was $194,736 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $203,588 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note II in the three or six months ended June 30, 2024 or 2023. On June 27, 2024, the maturity date on the March 2024 Dent Note I was extended until December 27, 2024 in exchange for a ten-year warrant to purchase 393,750 shares of the Company’s common stock at an exercise price of $0.081 per share. Because the discounted cash flows from the note before and after the extension were determined to be substantially different, the extension was treated as an extinguishment and reissuance. In connection with the extension, the Company recognized a loss on extinguishment of debt of $65,936 in the three and six months ended June 30, 2024 and the March 2024 Dent Note I was recorded at its fair value of $405,006. The Company recognized a gain on change in fair value of debt in the amount of $12,273 in the three and six months ended June 30, 2024 related to the change in fair value of the March 2024 Dent Note I between June 27 and June 30, 2024. The fair value and carrying value of the March 2024 Dent Note I as of June 30, 2024 was $392,733. The March 2024 Dent Note I will continue to be revalued at future period ends. Net proceeds from the March 2024 Dent Note II were $150,000. At inception, the Company recorded a discount of $89,222, representing the allocated fair value of the BCF and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note II. The discount is being amortized over the life of the note. Amortization of debt discount was $54,128 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $56,508 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note II in the three or six months ended June 30, 2024 or 2023. As of June 30, 2024 and December 31, 2023, remaining principal payments were $150,000 and $-0-, respectively, the net carrying value was $117,285 and $-0-, respectively. The March 2024 Dent Note III refinanced the previously issued December 2023 Dent Note in the same principal amount of $166,500. Because the two notes were determined to be substantially different, the issuance of the March 2024 Dent Note III and repayment of the December 2023 Dent Note was treated as an extinguishment and reissuance. Accordingly, the Company recognized a loss on debt extinguishment of $-0- and $96,660 in the three and six months ended June 30, 2024, respectively. The loss on debt extinguishment in the six month period was comprised of $63,539 for the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note III and $33,121 for the excess of the fair value of the March 2024 Dent Note III over the carrying value of the refinanced December 2023 Dent Note. The Company recognized a gain on change in fair value of debt in the amount of $15,627 in the three and six months ended June 30, 2024 related to the change in fair value of the March 2024 Dent Note III between March 31 and June 30, 2024. The fair value and carrying value of the March 2024 Dent Note III as of June 30, 2024 was $183,994. The March 2024 Dent Note I will continue to be revalued at future period ends. On April 10, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024 (the “April 2024 Dent Note I”). The April 2024 Dent Note I is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.0577 per share. The Company received net proceeds of $150,000. At inception, the Company recorded a note payable in the amount of $150,000 with no related discounts. No payments were made on the April 2024 Dent Note I in the three or six months ended June 30, 2024 or 2023. On April 18, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024 (the “April 2024 Dent Note II”). The April 2024 Dent Note II is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.05 per share. The Company received net proceeds of $50,000. At inception, the Company recorded a note payable in the amount of $50,000 with no related discounts. No payments were made on the April 2024 Dent Note II in the three or six months ended June 30, 2024 or 2023. On June 3, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $1,000,000, an interest rate of 12% per annum, and a maturity date of June 3, 2025 (the “June 2024 Dent Note”). The June 2024 Dent Note is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.0497 per share. The Company received net proceeds of $950,000 after original issue discount. In connection with the June 2024 Dent Note, the Company issued 10,000,000 ten-year warrants to the holder with an exercise price of $0.0497. The fair value of the warrants was $333,111. The fair value of the embedded BCF was $392,905. At inception, the Company recorded a note payable in the amount of $1,000,000 and a discount against the note payable of $785,811 for the allocated fair value of the BCF, original issue discount and warrants. The Company made no payments in the three or six months ended June 30, 2024 or 2023. Amortization of debt discount was $58,128 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $58,128 and $-0- in the six months ended June 30, 2024 and 2023, respectively. Interest accrued on notes and convertible notes payable to related parties as of June 30, 2024 and December 31, 2023 was $21,213 and $7,456, respectively. Interest expense on notes and convertible notes payable to related parties was $28,597 and $35,306 in the three months ended June 30, 2024 and 2023, respectively, and $24,549 and $40,196 in the six months ended June 30, 2024 and 2023, respectively. Deferred Compensation Payable to Dr. Michael Dent There was no activity related to deferred compensation payable to Dr. Michael Dent and therefore, as of June 30, 2024 and December 31, 2023, the balance was $300,600 and $300,600, respectively. Other Related Transactions Our outside directors each receive compensation equal to $20,000 in shares of restricted stock per annum. As of June 30, 2024 and December 31, 2023, the Company had 1,224,492 and 408,164 shares, respectively, issuable to our directors under such compensation arrangements. Consulting fees paid by the Company to Dr. Dent’s spouse were $33,462 and $22,308 in the three months ended June 30, 2024 and 2023, respectively, and $72,500 and $50,192 in the six months ended June 30, 2024 and 2023, respectively.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2024
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 12 – NOTES PAYABLE Notes payable as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 SBA Disaster Relief Loans $ 450,000 $ 450,000 1800 Diagonal Note Payable III, August 2023 — 97,279 Yorkville Note Payable III, November 2023 113,400 302,400 1800 Diagonal Note Payable III, December 2023 63,669 162,131 Yorkville Note Payable III, December 2023 81,000 189,000 1800 Diagonal Note Payable IV, April 2024 162,287 — Face value of notes payable 870,356 1,200,810 Less: unamortized discounts (77,613 ) (166,487 ) Notes payable, total 792,743 1,034,323 Less: long term portion (450,000 ) (450,000 ) Notes payable, current portion $ 342,743 $ 584,323 Government Notes Payable During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. The loans bear interest at 3.75% per annum and mature 30 years from issuance. Mandatory principal and interest payments were originally scheduled to begin 12 months from the inception date of each loan and were subsequently extended by the SBA until 30 months from the inception date. Installment payments, which are first applied to accrued but unpaid interest and then to principal, began in 2023. Interest accrued on SBA loans as of June 30, 2024 and December 31, 2023 was $22,376 and $27,628, respectively. Interest expense (income) recognized on the loans was $1,860 and ($11,001) in the three months ended June 30, 2024 and 2023, respectively, and $7,906 and ($6,783) in the six months ended June 30, 2024 and 2023, respectively. Payments against interest were $6,579 and $9,834 in the three months ended June 30, 2024 and 2023, respectively, and $13,158 and $14,951 in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, remaining principal payments were $450,000 and $450,000, respectively, and the net carrying value was $450,000 and $450,000, respectively. Other Notes Payable On July 19, 2022, pursuant to a Note Purchase Agreement between the Company and Yorkville, dated July 5, 2022, the Company issued to Yorkville a promissory note (the “Promissory Note”) with an initial stated principal amount equal to $550,000 at a purchase price equal to the principal amount of the Promissory Note less any original issue discounts and fees. The Promissory Note included a 5% original issue discount, accrues interest at a rate of 0%, and was scheduled to mature on January 19, 2023. The Company received net proceeds of $522,500. Each payment included a 2% payment premium, totaling $561,000 in total cash repayments. At inception, the Company recorded a discount against the note of $38,500, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. On November 15, 2022, the Company and Yorkville entered into an Amended and Restated Note (the “Amended Note”) to, among other things, extend the original note’s maturity date of January 19, 2023 to March 15, 2023. Amortization expense related to the discount was $-0- and $4,748 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $-0- in the three months ended June 30, 2024 and 2023, respectively. No On October 21, 2022, the Company issued a promissory note payable to an investor in the principal amount of $144,760 (the “October 2022 Note”). The October 2022 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The October 2022 Note did not bear interest in excess of the original issue discount and had a maturity date of October 31, 2023. The Company was required to make 10 monthly payments of $16,213 starting November 30, 2022 and ending August 31, 2023. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which was amortized over the repayment period. Amortization expense related to the note discount was $-0- and $10,865 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $21,610 in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $48,639 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $81,066 in the six months ended June 30, 2024 and 2023, respectively. The October 2022 Note was repaid in August 2023. On November 4, 2022, AEU borrowed a gross amount of $41,009 from a third-party lender, receiving net proceeds of $35,800 after fees and discounts (the “AEU Loan”). At inception of the note, the Company recognized a discount of $5,209. Amortization expense related to the note discount was $-0- and $1,621 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $3,988 in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $12,762 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $31,393 in the six months ended June 30, 2024 and 2023, respectively. The AEU Loan was repaid in June 2023. On March 10, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $116,760 and prepaid interest of $14,011 for total repayments of $130,771 (the “March 2023 Note”). The March 2023 Note had an original issue discount of $12,510 and fees of $4,250, resulting in net proceeds to the Company of $100,000. The March 2023 Note did not bear interest in excess of the original issue discount and matured on March 10, 2024. The Company was required to make 10 monthly payments of $13,077 starting April 30, 2023. At inception, the Company recorded a discount against the note of $30,771, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $-0- and $8,696 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $10,225 in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $-0- and $26,154 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $26,154 in the six months ended June 30, 2024 and 2023, respectively. The final installment payment was made in December 2023. On August 8, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “August 2023 Note”). The August 2023 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The August 2023 Note does not bear interest in excess of the original issue discount and matures on June 30, 2024. The Company is required to make 10 monthly payments of $16,213 starting September 30, 2023 and ending on June 30, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $10,365 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $13,098 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $64,852 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $97,279 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The final installment payment was made in April 2024. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $7,631 in the three and six months ended June 30, 2024. On November 3, 2023, the Company issued to Yorkville a note payable (the “November 2023 Note”) with an initial principal amount equal to $350,000 at a purchase price equal to the principal amount of the November 2023 Note less any original issue discounts and fees. The Company received net proceeds of $317,000. The November 2023 Note is scheduled to mature on September 3, 2024. The November 2023 Note accrues interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on December 3, 2023, with each payment including an 8% payment premium, totaling $378,000 in cash repayments. At inception, the Company recorded a discount against the note of $61,000, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $18,200 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $36,400 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $113,400 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $189,000 and $-0- in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, remaining payments were $113,400 and $302,400, respectively, and the net carrying value was $100,400 and $253,000, respectively. As June 30, 2024, the November 2023 Note was not in default and the Company was in compliance with the stated loan requirements. On December 12, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “December 2023 Note I”). The December 2023 Note I had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The December 2023 Note I does not bear interest in excess of the original issue discount and matures on October 15, 2024. The Company is required to make 10 monthly payments of $16,213 starting January 15, 2024 and ending on October 15, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. The December 2023 Note I gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. Amortization expense related to the note discount was $10,971 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $21,941 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $49,813 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $98,462 and $-0- in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, remaining payments were $63,669 and $162,131, respectively, and the net carrying value was $50,769 and $127,291, respectively. As June 30, 2024, the December 2023 Note I was not in default and the Company was in compliance with the stated loan requirements. On December 13, 2023, the Company issued to Yorkville a convertible note (the “December 2023 Note II”) with an initial principal amount equal to $175,000 at a purchase price equal to the principal amount of the December 2023 Note II less any original issue discounts and fees. The Company received net proceeds of $156,000. The December 2023 Note II is scheduled to mature on September 3, 2024. The December 2023 Note II accrues interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on March 3, 2024, with each payment including an 8% payment premium, totaling $189,000 in cash repayments. The December 2023 Note II is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.05 per share. At inception, the Company recorded a discount against the note of $66,000, representing the fair value of the conversion option and the difference between the total required repayments and the net proceeds received. The discount is being amortized over the repayment period. Amortization expense related to the note discount was $22,664 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $45,328 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $81,000 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $108,000 and $-0- in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, remaining payments were $81,000 and $189,000, respectively, and the net carrying value was $64,811 and $127,483, respectively. As June 30, 2024, the December 2023 Note II was not in default and the Company was in compliance with the stated loan requirements. On April 22, 2024, the Company issued a promissory note payable (the “April 2024 Note”) to an investor with a stated principal amount of $161,000 and prepaid interest of $19,320 for total repayments of $180,320. The Company received net proceeds of $118,787 after original issue discount of $21,000, fees of $5,000, and withholding of the final payment due on the August 2023 Note to the same investor in the amount of $16,213. The April 2024 Note does not bear interest in excess of the original issue discount and prepaid interest and matures on February 28, 2025. The Company is required to make 10 monthly payments of $18,032 starting May 30, 2024 and ending on February 28, 2025. The April 2024 Note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock only in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. Amortization expense related to the note discount was $9,795 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $9,795 and $-0- in the six months ended June 30, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $18,032 and $-0- in the three months ended June 30, 2024 and 2023, respectively, and $18,032 and $-0- in the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, remaining payments were $162,288 and $-0-, respectively, and the net carrying value was $126,763 and $-0-, respectively. As June 30, 2024, the April 2024 Note was not in default and the Company was in compliance with the stated loan requirements.

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2024
Shareholders' Equity (Deficit) [Abstract]
Shareholders' Equity (Deficit)	NOTE 13 – SHAREHOLDERS’ EQUITY (DEFICIT) SEPA Advances On July 5, 2022, the Company entered into the SEPA with Yorkville, pursuant to which the Company shall have the right, but not the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA advance (an “Advance”) may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022. During the six months ended June 30, 2023, the Company made one Advance under the SEPA, receiving $18,765 in proceeds for the issuance of 225,000 shares of common stock, all of which was applied to the balance of the Yorkville Promissory Note that was repaid in first quarter 2023. No Advances were made during the six months ended June 30, 2024. Private Placements During the three and six months ended June 30, 2024, the Company sold 877,193 and 5,977,193 shares of common stock, respectively, to one and four investors, respectively, in separate private placement transactions. The Company received $50,000 and $405,000 in proceeds from the sales in the three and six months ended June 30, 2024, respectively. In connection with the sales, the Company also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share in the three months ended March 31, 2024 and 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share in the three months ended June 30, 2024. During the three and six months ended June 30, 2023, the Company sold 5,416,667 and 7,416,667 shares of common stock, respectively, to two and three investors, respectively, in separate private placement transactions. The Company received $275,000 and $475,000 in proceeds from the sales in the three and six months ended June 30, 2024, respectively. In connection with the sales, the Company also issued 1,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.20 per share in the three months ended March 31, 2024 and 1,562,500 five-year warrants to purchase shares of common stock at exercise prices between $0.15 and $0.16 per share and a 3-month warrant to purchase 5,000,000 shares of common stock at an exercise price of $0.05 in the three months ended June 30, 2024. Shares issued to Consultants During the six months ended June 30, 2024, the Company issued to a consultant a ten-year stock option to purchase 2,504,974 shares of common stock at an exercise price equal of $0.0569 in satisfaction of common stock issuable accrued to the consultant for services provided between 2021 and 2024. Common Stock Issuable As of June 30, 2024 and December 31, 2023, the Company was obligated to issue the following shares: June 30, 2024 December 31, 2023 Amount Shares Amount Shares Shares issuable to employees and consultants $ 50,874 752,651 $ 261,682 2,356,188 Shares issuable to independent directors 60,000 1,224,492 20,000 408,164 $ 110,874 1,977,143 $ 281,682 2,764,352 Stock Warrants Transactions involving our stock warrants during the six months ended June 30, 2024 and 2023 are summarized as follows: 2024 2023 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 77,414,648 $ 0.20 68,109,094 $ 0.22 Granted during the period 19,992,346 $ 0.07 10,619,698 $ 0.10 Exercised during the period — $ — — $ — Expired during the period (1,342,402 ) $ (0.28 ) (3,662,333 ) $ (0.25 ) Outstanding at end of the period 96,064,592 $ 0.18 75,066,459 $ 0.21 Exercisable at end of the period 96,064,592 $ 0.18 75,066,459 $ 0.21 Weighted average remaining life 3.3 years 2.2 years The following table summarizes information about the Company’s stock warrants outstanding as of June 30, 2024: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 40,362,039 5.0 $ 0.06 40,362,039 $ 0.06 $ 0.10 to 0.24 25,875,536 2.8 $ 0.16 25,875,536 $ 0.16 $ 0.25 to 0.49 26,867,093 1.3 $ 0.31 26,867,093 $ 0.31 $ 0.50 to 1.05 2,959,924 2.0 $ 0.68 2,959,924 $ 0.68 $ 0.05 to 1.00 96,064,592 3.3 $ 0.18 96,064,592 $ 0.18 During the six months ended June 30, 2024 and 2023, the Company issued 19,992,346 and 10,619,698 warrants, respectively, the aggregate grant date fair value of which was $754,657 and $510,235, respectively. The fair value of the warrants was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 3.97% to 4.20% 3.60% to 4.27% Expected life range (in years) 5.00 years to 10.00 years 0.28 years to 5.00 years Volatility range 139.73% to 173.25% 126.30% to 141.2% Dividend yield 0.00% 0.00% Expected forfeiture 33.00% 20.00% There were no warrants exercised during the six months ended June 30, 2024 or 2023. Equity Incentive Plans On January 1, 2016, the Company adopted the 2016 Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2016 EIP allowed for the issuance of up to 15,503,680 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP is governed by the Board, or a committee that may be appointed by the Board in the future. The 2016 EIP expired during 2021 but allows for the prospective issuance of common shares upon vesting of stock awards or exercise of stock options granted prior to expiration of the 2016 EIP. On September 9, 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 EIP” and, together with the 2016 EIP, the “EIPs”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2021 EIP allows for the issuance of up to 20,000,000 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by the Board, or a committee that may be appointed by the Board in the future. Amounts recognized in the financial statements with respect to the EIPs in the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Total cost of share-based payment plans during the period $ 87,035 $ 76,402 $ 123,021 $ 159,353 Amounts capitalized in deferred equity compensation during period $ — $ — $ — $ — Amounts written off from deferred equity compensation during period $ — $ — $ 57,147 $ — Amounts charged against income for amounts previously capitalized $ — $ 5,204 $ — $ 10,354 Amounts charged against income, before income tax benefit $ 87,035 $ 81,606 $ 180,168 $ 169,707 Amount of related income tax benefit recognized in income $ — $ — $ — $ — Stock Options Stock options granted under the EIPs typically vest over a period of three to four years or based on achievement of Company and individual performance goals. The following table summarizes stock option activity as of and for the six months ended June 30, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Exercise Exercise Stock options Number Price Number Price Outstanding at beginning of period 5,093,738 $ 0.16 5,222,982 $ 0.20 Granted during the period 4,804,974 $ 0.06 93,750 $ 0.08 Exercised during the period — $ — — $ — Forfeited during the period (449,982 ) $ (0.21 ) (450,000 ) $ (0.16 ) Outstanding at end of period 9,448,730 $ 0.10 4,866,732 $ 0.17 Options exercisable at period-end 7,202,896 $ 0.11 3,110,815 $ 0.20 As of June 30, 2024, there was $79,525 of total unrecognized compensation cost related to options granted under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.4 years. The weighted-average grant-date fair value of options granted during the six months ended June 30, 2024 and 2023 was $0.04 and $0.05, respectively. The total fair value of options vested during the six months ended June 30, 2024 and 2023 was $147,568 and $35,954, respectively. No options were exercised during the six months ended June 30, 2024 or 2023. Stock based compensation expense related to stock options was $15,616 and $15,238 in the three months ended June 30, 2024 and 2023, respectively, and $63,515 and $37,748 in the six months ended June 30, 2024 and 2023, respectively. The fair value of each stock option award is estimated on the date of grant using a binomial lattice option-pricing model based on the assumptions noted in the following table. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. The fair value of options granted for the six months ended June 30, 2024 and 2023 was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 4.20% 3.48% Expected life range (in years) 10.00 years 10.00 years Volatility range 173.09% to 173.25% 145.03% Dividend yield 0.00% 0.00% Expected forfeiture 30.00% 30.00% The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the six months ended June 30, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock options Shares Fair Value Shares Fair Value Nonvested options at beginning of period 1,073,084 $ 0.06 2,260,417 $ 0.08 Granted 4,804,974 $ 0.04 93,750 $ 0.05 Vested (3,582,224 ) $ (0.04 ) (298,250 ) $ (0.12 ) Forfeited (50,000 ) $ (0.08 ) (300,000 ) $ (0.09 ) Nonvested options at end of period 2,245,834 $ 0.05 1,755,917 $ 0.07 Stock Grants Stock grant awards made under the EIPs typically vest either immediately or over a period of up to four years. The following table summarizes stock grant activity as of and for the six months ended June 30, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock Grants Shares Fair Value Shares Fair Value Nonvested grants at beginning of period 1,484,488 $ 0.05 1,651,435 $ 0.05 Granted — $ — 160,944 $ 0.09 Vested (821,328 ) $ (0.05 ) (981,584 ) $ (0.05 ) Forfeited (50,000 ) $ (0.12 ) (15,000 ) $ (0.26 ) Nonvested grants at end of period 613,160 $ 0.05 815,795 $ 0.05 As of June 30, 2024, there was $8,653 of total unrecognized compensation cost related to stock grants made under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.2 years. The weighted-average grant-date fair value of share grants made during the six months ended June 30, 2023 was $0.09 per share. No grants were made in the six months ended June 30, 2024. The aggregate fair value of share grants that vested during the six months ended June 30, 2024 and 2023 was $40,588 and $52,756, respectively. Stock based compensation expense related to stock grants was $1,796 and $24,172 in the three months ended June 30, 2024 and 2023, respectively, and $3,592 and $49,640 in the six months ended June 30, 2024 and 2023, respectively. The fair value of each stock grant is calculated using the closing sale price of the Company’s common stock on the date of grant. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. Liability-Classified Equity Instruments During 2021, the Company made certain stock grants from the 2021 EIP that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. During 2022, the Company made an additional grant of stock options from the 2021 EIP with a fixed fair value that may be earned based on achievement of performance targets on a quarterly basis through June 2025. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument” related to such instruments. Amortization of deferred stock compensation assets was $-0- and $5,203 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $10,353 in the six months ended June 30, 2024 and 2023, respectively. The Company subsequently de-recognized Deferred equity compensation and Liability-classified equity instruments upon termination of the instruments in 2022 and 2023 and no further equity-related assets or liabilities remained as of June 30, 2024.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Supplier Concentration The Company relied on a single supplier for the fulfillment of approximately 94% and 91% of its product sales made through MOD in the six months ended June 30, 2024 and 2023, respectively. Service Contracts The Company carries various service contracts on its office buildings and certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled. Leases Maturities of operating lease liabilities were as follows as of June 30, 2024: 2024 (July to December) $ 279,478 2025 477,584 2026 335,634 2027 990 Total lease payments 1,093,686 Less interest (291,649 ) Present value of lease liabilities $ 802,037 Employment/Consulting Agreements The Company has employment agreements with certain of its physicians, nurse practitioners and physical therapists in the Health Services Division. The agreements generally call for a fixed salary plus performance-based pay. On July 1, 2016, the Company entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. The Company is not aware of any such legal proceedings that will have, individually or in the aggregate, a material adverse effect on its business, financial condition or operating results.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 15 – SEGMENT REPORTING As of June 30, 2024, the Company had three reportable segments: Health Services, Digital Healthcare, and Medical Distribution. The Health Services Division is comprised of the operations of (i) NWC, a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice, (ii) NCFM, a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, (iii) BTG, a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) AEU, a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. The Digital Healthcare segment develops and plans to operate an online personal medical information and record archive system, the “HealthLynked Network,” which will enable patients and doctors to keep track of medical information via the Internet in a cloud-based system. The Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. On January 17, 2023, the Company entered into the AHP Merger Agreement pursuant to which the Company sold AHP and discontinued the operations of CHM, comprising its ACO/MSO Division. The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. See Note 4, “Discontinued Operations,” for additional information. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Segment information for the three months ended June 30, 2024 was as follows: Three Months Ended June 30, 2024 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 763,163 $ — $ — $ 763,163 Subscription revenue — 8,166 — 8,166 Product revenue — — 23,749 23,749 Total revenue 763,163 8,166 23,749 795,078 Operating Expenses Practice salaries and benefits 513,891 — — 513,891 Other practice operating expenses 389,222 — — 389,222 Cost of product revenue — — 24,723 24,723 Selling, general and administrative expenses — 842,524 18,945 861,469 Depreciation and amortization 83,922 1,340 — 85,262 Total Operating Expenses 987,035 843,864 43,668 1,874,567 (Loss) income from operations $ (223,872 ) $ (835,698 ) $ (19,919 ) $ (1,079,489 ) Other Segment Information Loss on extinguishment of debt $ — $ 73,567 $ — $ 73,567 Change in fair value of debt $ — $ (27,900 ) $ — $ (27,900 ) Amortization of original issue discounts on notes payable $ — $ 371,356 $ — $ 371,356 Change in fair value of contingent acquisition consideration $ — $ (635 ) $ — $ (635 ) Interest expense (income) $ 4,567 $ 39,992 $ — $ 44,559 Segment information for the six months ended June 30, 2024 was as follows: Six Months ended June 30, 2024 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 1,726,784 $ — $ — $ 1,726,784 Subscription revenue — 15,794 — 15,794 Product and other revenue — — 56,732 56,732 Total revenue 1,726,784 15,794 56,732 1,799,310 Operating Expenses Practice salaries and benefits 1,097,047 — — 1,097,047 Other practice operating expenses 871,805 — — 871,805 Cost of product revenue — — 55,302 55,302 Selling, general and administrative expenses — 1,822,698 38,214 1,860,912 Depreciation and amortization 169,091 2,680 — 171,771 Total Operating Expenses 2,137,943 1,825,378 93,516 4,056,837 Income (loss) from operations $ (411,159 ) $ (1,809,584 ) $ (36,784 ) $ (2,257,527 ) Other Segment Information Loss on extinguishment of debt $ — $ 170,227 $ — $ 170,227 Change in fair value of debt $ — $ (27,900 ) $ — $ (27,900 ) Amortization of original issue discounts on notes payable $ — $ 479,621 $ — $ 479,621 Change in fair value of contingent acquisition consideration $ — $ (711 ) $ — $ (711 ) Interest expense $ 5,517 $ 43,873 $ — $ 49,390 Identifiable Assets Identifiable assets as of June 30, 2024 $ 1,554,359 $ 2,285,209 $ 20,096 $ 3,859,664 Identifiable assets as of December 31, 2023 $ 1,812,609 $ 2,457,849 $ 9,682 $ 4,280,140 Segment information for the three months ended June 30, 2023 was as follows: Three Months Ended June 30, 2023 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 1,630,334 $ — $ — $ 1,630,334 Subscription revenue — 19,177 — 19,177 Product revenue — — 53,985 53,985 Total revenue 1,630,334 19,177 53,985 1,703,496 Operating Expenses Practice salaries and benefits 898,992 — — 898,992 Other practice operating expenses 646,216 — — 646,216 Cost of product revenue — — 34,397 34,397 Selling, general and administrative expenses — 803,012 30,677 833,689 Depreciation and amortization 86,887 1,406 — 88,293 Total Operating Expenses 1,632,095 804,418 65,074 2,501,587 Loss from operations $ (1,761 ) $ (785,241 ) $ (11,089 ) $ (798,091 ) Other Segment Information Loss on extinguishment of debt $ — $ 44,169 $ — $ 44,169 Amortization of original issue discounts on notes payable $ — $ 128,689 $ — $ 128,689 Gain from realization of contingent sale consideration receivable $ — $ (15,000 ) $ — $ (15,000 ) Change in fair value of contingent acquisition consideration $ — $ (6,070 ) $ — (6,070 ) Interest expense (income) $ 4,191 $ 34,933 $ — $ 39,124 Segment information for the six months ended June 30, 2023 was as follows: Six Months Ended June 30, 2023 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 3,330,615 $ — $ — $ 3,330,615 Subscription revenue — 35,476 — 35,476 Product and other revenue — — 92,559 92,559 Total revenue 3,330,615 35,476 92,559 3,458,650 Operating Expenses Practice salaries and benefits 1,862,649 — — 1,862,649 Other practice operating expenses 1,270,463 — — 1,270,463 Cost of product revenue — — 66,457 66,457 Selling, general and administrative expenses — 1,873,333 64,104 1,937,437 Depreciation and amortization 173,559 2,811 — 176,370 Total Operating Expenses 3,306,671 1,876,144 130,561 5,313,376 Income (loss) from operations $ 23,944 $ (1,840,668 ) $ (38,002 ) $ (1,854,726 ) Other Segment Information Loss on extinguishment of debt $ — $ 88,932 $ — $ 88,932 Amortization of original issue discounts on notes payable $ 3,988 $ 188,061 $ — $ 192,049 Gain from realization of contingent sale consideration receivable $ — $ 15,000 $ — $ 15,000 Change in fair value of contingent acquisition consideration $ — $ (4,364 ) $ — $ (4,364 ) Interest expense (income) $ 7,003 $ 43,502 $ — $ 50,505 Identifiable Assets Identifiable assets as of June 30, 2023 $ 2,061,059 $ 3,121,024 $ 23,075 $ 5,205,158 Goodwill as of June 30, 2023 $ 319,958 $ — $ — $ 319,958 The Digital Healthcare made intercompany sales of $336 and $120 in the three months ended June 30, 2024 and 2023, respectively, and $516 and $300 in the six months ended June 30, 2024 and 2023, respectively, related to subscription revenue billed to and paid for by the Company’s physicians for access to the HealthLynked Network. The Medical Distribution segment made intercompany sales of $-0- and $5,013 in the three months ended June 30, 2024 and 2023, respectively, and $-0- and $13,353 in the six months ended June 30, 2024 and 2023, respectively, related to medical products sold to practices in the Company’s Health Services segment. Intercompany revenue and the related costs are eliminated on consolidation.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2024
Fair Value of Financial Instruments [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 16 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans, which were extinguished and reissued and are therefore subject to fair value measurement, derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate was not fixed, and equity-class. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023: As of June 30, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Contingent sale consideration receivable $ — $ — $ 1,663,163 $ 1,663,163 $ — $ — $ 1,663,163 $ 1,663,163 Liabilities: Contingent acquisition consideration payable — — 1,479 1,479 — — 2,189 2,189 Convertible notes payable to related party — — 576,727 576,727 — — — — $ — $ — $ 578,206 $ 578,206 $ — $ — $ 2,189 $ 2,189 Certain notes payable to a related party carried at fair value and contingent acquisition consideration payable are each Level 3 financial instrument that are measured at fair value on a recurring basis. Gains (losses) from the change in fair value of Level 3 financial instruments during the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Change in fair value of debt $ 27,900 $ — $ 27,900 $ — Contingent acquisition consideration payable $ 635 $ 6,070 $ 711 $ 4,364 Total $ 28,535 $ 6,070 $ 28,611 $ 4,364

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS During July 2024, Dr. Michael Dent made advances to the Company in the amount of $235,000 that have not been documented as notes payable. The Company expects to issue notes payable for such amounts during the third quarter of 2024. On August 1, 2024, the Company’s wholly-owned subsidiary, HLYK Florida LLC, completed a Business Funding Agreement pursuant to which the Company borrowed net proceeds of $200,000. Pursuant to the borrowing arrangement, the Company is obligated to repay a total of $223,649 in 24 equal monthly installments.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,540,436)	$ (1,387,718)	$ (1,003,455)	$ 1,451,935	$ (2,928,154)	$ 448,480

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.
Revenue Recognition	Revenue Recognition Patient service revenue Patient service revenue is earned for patient services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time includes revenue from NCFM annual access contracts (the Medical Membership and Concierge Program prior to October 1, 2023 and the more comprehensive Optimal Health 365 Access Plan thereafter), NWC annual administration fees, and BTG physical therapy bundles. Revenue from NCFM Medical Memberships and Concierge contracts and NWC annual administration fees, which include bundled products and services that have substantially the same pattern of transfer to the customer, is recognized over the period of delivery, which is the same as the period of the contract (typically, one year). Revenue from prepaid BTG physical therapy bundles, for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual visits incurred in relation to total expected visits. At inception of such contracts, the Company recognizes contract liabilities for the value of services to be provided and, where applicable, contract assets for recoverable amounts incurred to obtain a customer contract that would not have incurred if the contract had not been obtained. The Company believes that these methods provide a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than NCFM annual access contracts, NWC annual administration fees, and BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient. Patient service revenues are presented on the statement of operations net of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the six months ended June 30, 2024 or 2023 to the judgments applied in determining the amount and timing of patient service revenue. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates; ● Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member. ● Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and for those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers. Product and Other Revenue Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue are recognized when payment is received but for which the Company has not met its product fulfillment performance obligation. Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States. The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $-0- and $-0- in cash balances in excess of the FDIC insured limit as of June 30, 2024 and December 31, 2023, respectively.
Accounts Receivable	Accounts Receivable Trade receivables related to NWC services billed to third party payors are carried at the estimated collectible amount, which is the standard charge based on the Company’ list price, net of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 61% of total gross billings. Trade accounts receivable are recorded at this net amount. As of June 30, 2024 and December 31, 2023, the Company’s gross patient services accounts receivable were $63,733 and $34,481, respectively, and net patient services accounts receivable were $38,559 and $20,861, respectively, based upon net reporting of accounts receivable. As of June 30, 2024 and December 31, 2023, the Company’s allowance for doubtful accounts was $-0- and $-0-, respectively.
Other Comprehensive Income	Other Comprehensive Income The Company does not have any activity that results in Other Comprehensive Income.
Leases	Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein.
Inventory	Inventory Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold.
Intangible Assets	Intangible Assets The Company recognizes an acquired intangible whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Fair Value of Assets and Liabilities	Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities; ● Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data; ● Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability. The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation to employees and nonemployees under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted.
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the six months ended June 30, 2024 since the Company sustained a loss in that period. No income tax was provided for the six months ended June 30, 2023 because the Company had sufficient operating loss carryforwards to offset any net income for the full year 2023, including income from capital gains related to the disposal of discontinued operations. The Company recognized net loss for the full year 2023. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.
Recurring Fair Value Measurements	Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, accounts payable, and accrued liabilities approximated their fair value.
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the six months ended June 30, 2024 and 2023, the Company reported a loss from continuing operations. As a result, diluted net income (loss) per common share is computed in the same manner as basic net income (loss) per common share, even though the Company had net income in the six months ended June 30, 2023 after adjusting for discontinued operations. The Company excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of June 30, 2024 and December 31, 2023, potentially dilutive securities were comprised of (i) 96,064,592 and 77,414,648 warrants outstanding, respectively, (ii) 9,448,730 and 5,093,738 stock options outstanding, respectively, (iii) 613,160 and 1,484,488 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,977,143 and 2,764,352 common shares issuable that are earned but not paid under consulting and director compensation arrangements, (v) up to 36,972,139 and 3,780,000 shares potentially issuable upon conversion of outstanding fixed price convertible notes payable, and (vi) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred.
Common Stock Awards	Common Stock Awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable.
Warrants	Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has three operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices). The Company’s ACO/MSO segment was sold on January 17, 2023. As described in further detail in Note 4, “Discontinued Operations,” this unit’s assets and liabilities are classified as held for sale as of December 31, 2022 and the unit’s results of operations are classified as “Income (loss) from operations of discontinued operations” in the three and six months ended June 30, 2024 and 2023.
Recently Adopted Pronouncements	Recently Adopted Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments.” The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company adopted this standard for the year ended December 31, 2023. The adoption did not have a material effect on the Company’s consolidated financial statements. In October 2021, the FASB issued guidance which requires companies to apply Topic 606, Revenue from Contracts with Customers In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the six months ended June 30, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the six months ended June 30, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2024
Discontinued Operations [Abstract]
Schedule of Financial Results of the ACO/MSO Division	The following table presents financial results of the ACO/MSO Division for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended 2024 2023 2024 2023 Revenue: Consulting revenue $ — $ — $ — $ 23,646 Total revenue — — — 23,646 Operating Expenses and Costs: Medicare shared savings expenses — 14,452 — 82,387 Loss from operations of discontinued operations before income taxes — (14,452 ) — (58,741 ) Provision for income taxes — — — — Loss from discontinued operations, net of income taxes $ — $ (14,452 ) $ — $ (58,741 )
Schedule of Fair Value of Consideration Received and Receivable	The fair value of consideration received and receivable is shown in the following table: Upfront Cash Consideration paid at signing $ 750,000 Incremental Cash Consideration 1,311,567 IPO Share Consideration 1,463,517 2022 MSSP Consideration 312,987 Physician Advance Consideration 199,645 Stub Period Reimbursement 31,381 Total fair value of contingent consideration receivable 3,319,097 Total fair value of consideration received and receivable $ 4,069,097
Schedule of Assets and Liabilities Derecognized	The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows: Prepaid expenses $ 1,500 Intangible asset - ACO physician contract 1,073,000 Goodwill 381,856 Contract liability (20,278 ) Contingent acquisition consideration (185,024 ) Net Book Value of Assets and Liabilities Sold $ 1,251,054
Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities	After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the six months ended June 30, 2023 as follows: Total fair value of consideration received and receivable $ 4,069,097 Less: net book value of assets and liabilities sold (1,251,054 ) Less: fair value of Indemnification Clause (143,974 ) Gain from disposal of discontinued operations $ 2,674,069
Schedule of Remaining Unresolved Components of Contingent Consideration Receivable	The carrying value of the remaining unresolved components of contingent consideration receivable as of June 30, 2024 and December 31, 2023 was as follows: IPO Share Consideration $ 1,463,518 Physician Advance Consideration 199,645 Remaining contingent sale consideration receivable $ 1,663,163

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	6 Months Ended
	Jun. 30, 2024
Prepaid Expenses and Other [Abstract]
Schedule of Prepaid and Other Expenses	Prepaid and other expenses as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Insurance prepayments $ 8,099 $ 11,209 Other expense prepayments 18,379 38,391 Rent deposits 50,047 50,547 Contract assets 8,264 5,110 Total prepaid expenses and other 84,789 105,257 Less: long term portion (50,047 ) (50,047 ) Prepaid expenses and other, current portion $ 34,742 $ 55,210

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Medical equipment $ 496,452 $ 493,854 Furniture, office equipment and leasehold improvements 317,963 317,963 Total property and equipment 814,415 811,817 Less: accumulated depreciation (580,062 ) (521,062 ) Property and equipment, net $ 234,353 $ 290,755

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Intangible Assets [Abstract]
Schedule of Intangible Assets	Identifiable intangible assets as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 NCFM: Medical database $ 1,101,538 $ 1,101,538 NCFM: Website 41,000 41,000 Total intangible assets 1,142,538 1,142,538 Less: accumulated amortization (371,461 ) (258,690 ) Intangible assets, net $ 771,077 $ 883,848
Schedule of Future Amortization Expense of Intangible Assets	Future amortization expense of intangible assets is expected to be as follows: 2024 (July to December) $ 110,154 2025 220,308 2026 220,308 2027 220,307 Thereafter — Total future amortization expense $ 771,077

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of Lease-Related Assets and Liabilities	The table below summarizes the Company’s lease-related assets and liabilities as of June 30, 2024 and December 31, 2023: June 30, December 31, 2024 2023 Lease assets $ 798,593 $ 935,812 Lease liabilities Lease liabilities (short term) $ 363,482 $ 326,033 Lease liabilities (long term) 438,555 613,386 Total lease liabilities $ 802,037 $ 939,419
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities were as follows as of June 30, 2024: 2024 (July to December) $ 279,478 2025 477,584 2026 335,634 2027 990 Total lease payments 1,093,686 Less interest (291,649 ) Present value of lease liabilities $ 802,037

Accounts Payable, Accrued Exp_2

Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Accounts Payable, Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities	Amounts related to accounts payable, accrued expenses and other current liabilities as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Trade accounts payable $ 527,645 $ 251,479 Accrued payroll liabilities 99,282 110,103 Accrued operating expenses 73,007 91,238 Accrued interest 65,579 57,074 Accrued commissions payable from 2022 MSSP Consideration 25,000 100,000 Contingent acquisition consideration payable 1,479 2,189 Product return allowance 2,354 2,095 $ 794,346 $ 614,178

Contract Liabilities (Tables)

Contract Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Contract Liabilities [Abstract]
Schedule of Amounts Related to Contract Liabilities	Amounts related to contract liabilities as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 Patient services paid but not provided - NCFM $ 144,966 $ 95,334 Patient services paid but not provided - BTG 88,256 100,857 Patient services paid but not provided - NWC 50,029 75,438 Unshipped products - MOD 962 145 $ 284,213 $ 271,774

Amounts Due to Related Party _2

Amounts Due to Related Party and Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Amounts Due to Related Party and Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	Amounts due to related parties as of June 30, 2024 and December 31, 2023 were comprised of the following: June 30, December 31, 2024 2023 Note Payable to Dr. Michael Dent, March 2023 $ — $ 12,601 Note Payable to Dr. Michael Dent, June 2023 — 26,875 Note Payable to Dr. Michael Dent, December 2023 — 166,500 Convertible Note Payable I to Dr. Michael Dent, March 2024 150,000 — Convertible Note Payable II to Dr. Michael Dent, March 2024 ** 392,733 — Convertible Note Payable III to Dr. Michael Dent, March 2024 ** 183,994 — Convertible Note Payable IV to Dr. Michael Dent, April 2024 150,000 — Convertible Note Payable V to Dr. Michael Dent, April 2024 50,000 — Convertible Note Payable VI to Dr. Michael Dent, June 2024 1,000,000 — Face value of notes payable to related party 1,926,727 205,976 Less: unamortized discounts (760,397 ) (34,834 ) Notes payable to related party, total 1,166,330 171,142 Plus deferred compensation payable to Dr. Michael Dent 300,600 300,600 Total due to related party $ 1,466,930 $ 471,742 ** - denotes note payable carried at fair value

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Payable [Abstract]
Schedule of Notes Payable	Notes payable as of June 30, 2024 and December 31, 2023 were as follows: June 30, December 31, 2024 2023 SBA Disaster Relief Loans $ 450,000 $ 450,000 1800 Diagonal Note Payable III, August 2023 — 97,279 Yorkville Note Payable III, November 2023 113,400 302,400 1800 Diagonal Note Payable III, December 2023 63,669 162,131 Yorkville Note Payable III, December 2023 81,000 189,000 1800 Diagonal Note Payable IV, April 2024 162,287 — Face value of notes payable 870,356 1,200,810 Less: unamortized discounts (77,613 ) (166,487 ) Notes payable, total 792,743 1,034,323 Less: long term portion (450,000 ) (450,000 ) Notes payable, current portion $ 342,743 $ 584,323

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2024
Shareholders’ Equity (Deficit) [Line Items]
Schedule of Company Obligated to Issue Shares	As of June 30, 2024 and December 31, 2023, the Company was obligated to issue the following shares: June 30, 2024 December 31, 2023 Amount Shares Amount Shares Shares issuable to employees and consultants $ 50,874 752,651 $ 261,682 2,356,188 Shares issuable to independent directors 60,000 1,224,492 20,000 408,164 $ 110,874 1,977,143 $ 281,682 2,764,352
Schedule of Financial Statements with Respect to the EIPs	Amounts recognized in the financial statements with respect to the EIPs in the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Total cost of share-based payment plans during the period $ 87,035 $ 76,402 $ 123,021 $ 159,353 Amounts capitalized in deferred equity compensation during period $ — $ — $ — $ — Amounts written off from deferred equity compensation during period $ — $ — $ 57,147 $ — Amounts charged against income for amounts previously capitalized $ — $ 5,204 $ — $ 10,354 Amounts charged against income, before income tax benefit $ 87,035 $ 81,606 $ 180,168 $ 169,707 Amount of related income tax benefit recognized in income $ — $ — $ — $ —
Stock Warrants [Member]
Shareholders’ Equity (Deficit) [Line Items]
Schedule of Stock Warrants	Transactions involving our stock warrants during the six months ended June 30, 2024 and 2023 are summarized as follows: 2024 2023 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 77,414,648 $ 0.20 68,109,094 $ 0.22 Granted during the period 19,992,346 $ 0.07 10,619,698 $ 0.10 Exercised during the period — $ — — $ — Expired during the period (1,342,402 ) $ (0.28 ) (3,662,333 ) $ (0.25 ) Outstanding at end of the period 96,064,592 $ 0.18 75,066,459 $ 0.21 Exercisable at end of the period 96,064,592 $ 0.18 75,066,459 $ 0.21 Weighted average remaining life 3.3 years 2.2 years
Schedule of Financial Statements with Respect to the EIPs	The following table summarizes information about the Company’s stock warrants outstanding as of June 30, 2024: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 40,362,039 5.0 $ 0.06 40,362,039 $ 0.06 $ 0.10 to 0.24 25,875,536 2.8 $ 0.16 25,875,536 $ 0.16 $ 0.25 to 0.49 26,867,093 1.3 $ 0.31 26,867,093 $ 0.31 $ 0.50 to 1.05 2,959,924 2.0 $ 0.68 2,959,924 $ 0.68 $ 0.05 to 1.00 96,064,592 3.3 $ 0.18 96,064,592 $ 0.18
Schedule of Aggregate Grant Date Fair Value	The fair value of the warrants was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 3.97% to 4.20% 3.60% to 4.27% Expected life range (in years) 5.00 years to 10.00 years 0.28 years to 5.00 years Volatility range 139.73% to 173.25% 126.30% to 141.2% Dividend yield 0.00% 0.00% Expected forfeiture 33.00% 20.00%
Stock Options [Member]
Shareholders’ Equity (Deficit) [Line Items]
Schedule of Stock Options	The following table summarizes stock option activity as of and for the six months ended June 30, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Exercise Exercise Stock options Number Price Number Price Outstanding at beginning of period 5,093,738 $ 0.16 5,222,982 $ 0.20 Granted during the period 4,804,974 $ 0.06 93,750 $ 0.08 Exercised during the period — $ — — $ — Forfeited during the period (449,982 ) $ (0.21 ) (450,000 ) $ (0.16 ) Outstanding at end of period 9,448,730 $ 0.10 4,866,732 $ 0.17 Options exercisable at period-end 7,202,896 $ 0.11 3,110,815 $ 0.20
Schedule of Fair Value of Options Granted	The fair value of options granted for the six months ended June 30, 2024 and 2023 was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 4.20% 3.48% Expected life range (in years) 10.00 years 10.00 years Volatility range 173.09% to 173.25% 145.03% Dividend yield 0.00% 0.00% Expected forfeiture 30.00% 30.00%
Schedule of Stock Grant Activity	The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the six months ended June 30, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock options Shares Fair Value Shares Fair Value Nonvested options at beginning of period 1,073,084 $ 0.06 2,260,417 $ 0.08 Granted 4,804,974 $ 0.04 93,750 $ 0.05 Vested (3,582,224 ) $ (0.04 ) (298,250 ) $ (0.12 ) Forfeited (50,000 ) $ (0.08 ) (300,000 ) $ (0.09 ) Nonvested options at end of period 2,245,834 $ 0.05 1,755,917 $ 0.07
Stock Grants [Member]
Shareholders’ Equity (Deficit) [Line Items]
Schedule of Stock Grant Activity	The following table summarizes stock grant activity as of and for the six months ended June 30, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock Grants Shares Fair Value Shares Fair Value Nonvested grants at beginning of period 1,484,488 $ 0.05 1,651,435 $ 0.05 Granted — $ — 160,944 $ 0.09 Vested (821,328 ) $ (0.05 ) (981,584 ) $ (0.05 ) Forfeited (50,000 ) $ (0.12 ) (15,000 ) $ (0.26 ) Nonvested grants at end of period 613,160 $ 0.05 815,795 $ 0.05

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2024
Operating lease [Member]
Commitments and Contingencies [Line Items]
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities were as follows as of June 30, 2024: 2024 (July to December) $ 279,478 2025 477,584 2026 335,634 2027 990 Total lease payments 1,093,686 Less interest (291,649 ) Present value of lease liabilities $ 802,037

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	Segment information for the three months ended June 30, 2024 was as follows: Three Months Ended June 30, 2024 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 763,163 $ — $ — $ 763,163 Subscription revenue — 8,166 — 8,166 Product revenue — — 23,749 23,749 Total revenue 763,163 8,166 23,749 795,078 Operating Expenses Practice salaries and benefits 513,891 — — 513,891 Other practice operating expenses 389,222 — — 389,222 Cost of product revenue — — 24,723 24,723 Selling, general and administrative expenses — 842,524 18,945 861,469 Depreciation and amortization 83,922 1,340 — 85,262 Total Operating Expenses 987,035 843,864 43,668 1,874,567 (Loss) income from operations $ (223,872 ) $ (835,698 ) $ (19,919 ) $ (1,079,489 ) Other Segment Information Loss on extinguishment of debt $ — $ 73,567 $ — $ 73,567 Change in fair value of debt $ — $ (27,900 ) $ — $ (27,900 ) Amortization of original issue discounts on notes payable $ — $ 371,356 $ — $ 371,356 Change in fair value of contingent acquisition consideration $ — $ (635 ) $ — $ (635 ) Interest expense (income) $ 4,567 $ 39,992 $ — $ 44,559 Six Months ended June 30, 2024 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 1,726,784 $ — $ — $ 1,726,784 Subscription revenue — 15,794 — 15,794 Product and other revenue — — 56,732 56,732 Total revenue 1,726,784 15,794 56,732 1,799,310 Operating Expenses Practice salaries and benefits 1,097,047 — — 1,097,047 Other practice operating expenses 871,805 — — 871,805 Cost of product revenue — — 55,302 55,302 Selling, general and administrative expenses — 1,822,698 38,214 1,860,912 Depreciation and amortization 169,091 2,680 — 171,771 Total Operating Expenses 2,137,943 1,825,378 93,516 4,056,837 Income (loss) from operations $ (411,159 ) $ (1,809,584 ) $ (36,784 ) $ (2,257,527 ) Other Segment Information Loss on extinguishment of debt $ — $ 170,227 $ — $ 170,227 Change in fair value of debt $ — $ (27,900 ) $ — $ (27,900 ) Amortization of original issue discounts on notes payable $ — $ 479,621 $ — $ 479,621 Change in fair value of contingent acquisition consideration $ — $ (711 ) $ — $ (711 ) Interest expense $ 5,517 $ 43,873 $ — $ 49,390 Identifiable Assets Identifiable assets as of June 30, 2024 $ 1,554,359 $ 2,285,209 $ 20,096 $ 3,859,664 Identifiable assets as of December 31, 2023 $ 1,812,609 $ 2,457,849 $ 9,682 $ 4,280,140 Three Months Ended June 30, 2023 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 1,630,334 $ — $ — $ 1,630,334 Subscription revenue — 19,177 — 19,177 Product revenue — — 53,985 53,985 Total revenue 1,630,334 19,177 53,985 1,703,496 Operating Expenses Practice salaries and benefits 898,992 — — 898,992 Other practice operating expenses 646,216 — — 646,216 Cost of product revenue — — 34,397 34,397 Selling, general and administrative expenses — 803,012 30,677 833,689 Depreciation and amortization 86,887 1,406 — 88,293 Total Operating Expenses 1,632,095 804,418 65,074 2,501,587 Loss from operations $ (1,761 ) $ (785,241 ) $ (11,089 ) $ (798,091 ) Other Segment Information Loss on extinguishment of debt $ — $ 44,169 $ — $ 44,169 Amortization of original issue discounts on notes payable $ — $ 128,689 $ — $ 128,689 Gain from realization of contingent sale consideration receivable $ — $ (15,000 ) $ — $ (15,000 ) Change in fair value of contingent acquisition consideration $ — $ (6,070 ) $ — (6,070 ) Interest expense (income) $ 4,191 $ 34,933 $ — $ 39,124 Six Months Ended June 30, 2023 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 3,330,615 $ — $ — $ 3,330,615 Subscription revenue — 35,476 — 35,476 Product and other revenue — — 92,559 92,559 Total revenue 3,330,615 35,476 92,559 3,458,650 Operating Expenses Practice salaries and benefits 1,862,649 — — 1,862,649 Other practice operating expenses 1,270,463 — — 1,270,463 Cost of product revenue — — 66,457 66,457 Selling, general and administrative expenses — 1,873,333 64,104 1,937,437 Depreciation and amortization 173,559 2,811 — 176,370 Total Operating Expenses 3,306,671 1,876,144 130,561 5,313,376 Income (loss) from operations $ 23,944 $ (1,840,668 ) $ (38,002 ) $ (1,854,726 ) Other Segment Information Loss on extinguishment of debt $ — $ 88,932 $ — $ 88,932 Amortization of original issue discounts on notes payable $ 3,988 $ 188,061 $ — $ 192,049 Gain from realization of contingent sale consideration receivable $ — $ 15,000 $ — $ 15,000 Change in fair value of contingent acquisition consideration $ — $ (4,364 ) $ — $ (4,364 ) Interest expense (income) $ 7,003 $ 43,502 $ — $ 50,505 Identifiable Assets Identifiable assets as of June 30, 2023 $ 2,061,059 $ 3,121,024 $ 23,075 $ 5,205,158 Goodwill as of June 30, 2023 $ 319,958 $ — $ — $ 319,958

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value of Financial Instruments [Abstract]
Schedule of Fair Value Measurements	The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023: As of June 30, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Contingent sale consideration receivable $ — $ — $ 1,663,163 $ 1,663,163 $ — $ — $ 1,663,163 $ 1,663,163 Liabilities: Contingent acquisition consideration payable — — 1,479 1,479 — — 2,189 2,189 Convertible notes payable to related party — — 576,727 576,727 — — — — $ — $ — $ 578,206 $ 578,206 $ — $ — $ 2,189 $ 2,189
Schedule of Gains (Losses) from the Change in Fair Value of Level 3 Financial Instruments	Gains (losses) from the change in fair value of Level 3 financial instruments during the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Change in fair value of debt $ 27,900 $ — $ 27,900 $ — Contingent acquisition consideration payable $ 635 $ 6,070 $ 711 $ 4,364 Total $ 28,535 $ 6,070 $ 28,611 $ 4,364

Business and Business Present_2

Business and Business Presentation (Details) - shares	Jun. 30, 2024	Dec. 31, 2023	Feb. 05, 2018	Sep. 02, 2014
Business and Business Presentation [Line Items]
Number of authorized shares				250,000,000
Common stock shares authorized	500,000,000	500,000,000
Common Stock [Member]
Business and Business Presentation [Line Items]
Common stock shares authorized			500,000,000	230,000,000
Preferred Stock [Member]
Business and Business Presentation [Line Items]
Preferred stock shares authorized				20,000,000

Significant Accounting Polici_2

Significant Accounting Policies (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Significant Accounting Policies [Line Items]
FDIC insurance amount (in Dollars)	$ 250,000
Cash balances in excess of FDICI insured limit (in Dollars)	$ 0	$ 0
Percentage of customers accounts receivable billings	61%
Gross patient services accounts receivable (in Dollars)	$ 63,733	34,481
Account receivable net (in Dollars)	38,559	20,861
Allowance of doubtful accounts (in Dollars)	$ 0	$ 0
Number of operating segments	3
Warrant [Member]
Significant Accounting Policies [Line Items]
Potentially dilutive securities.	96,064,592	77,414,648
Equity Option [Member]
Significant Accounting Policies [Line Items]
Potentially dilutive securities.	9,448,730	5,093,738
Employee Incentive Plan [Member]
Significant Accounting Policies [Line Items]
Potentially dilutive securities.	613,160	1,484,488
Director Compensation [Member]
Significant Accounting Policies [Line Items]
Potentially dilutive securities.	1,977,143	2,764,352
Convertible Notes Payable [Member]
Significant Accounting Policies [Line Items]
Potentially dilutive securities.	36,972,139	3,780,000
Series B Preferred [Member]
Significant Accounting Policies [Line Items]
Potentially dilutive securities.	13,750,000	13,750,000
Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	7 years

Liquidity and Going Concern A_2

Liquidity and Going Concern Analysis (Details) - USD ($)							3 Months Ended				6 Months Ended
	Aug. 31, 2023	Jul. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Jan. 17, 2023	Jul. 05, 2022	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Liquidity and Going Concern Analysis (Details) [Line Items]
Cash balance							$ 172,700				$ 172,700		$ 247,222
Working capital deficit											1,390,094
Capital deficit							(44,961,290)				(44,961,290)		$ (42,033,136)
Net Income (Loss)							$ (1,540,436)	$ (1,387,718)	$ (1,003,455)	$ 1,451,935	(2,928,154)	$ 448,480
Cash from operating activities											(1,713,549)	$ (1,703,255)
Agreement amount											500,000
Proceed from debt											1,785,000
Notes payable to related parties											$ 548,375
Shares of common stock (in Shares)						30,000,000			5,416,667			7,416,667
Common stock, par value (in Dollars per share)							$ 0.0001				$ 0.0001		$ 0.0001
AHP Merger Agreement [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Agreement amount				$ 31,381	$ 750,000
Net incremental consideration	$ 1,750,000	$ 1,750,000	$ 1,750,000				$ 500,000		$ 1,750,000		$ 500,000	$ 1,750,000
Net after commissions	$ 1,540,000	$ 1,540,000	$ 1,540,000								$ 1,873,993
Transfer milestones rate											100%
Other expenses											$ 1,186,231
Common Stock [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Proceeds from the sale of common stock											$ 405,000
Common stock, par value (in Dollars per share)						$ 0.0001
Common Stock [Member] | SEPA [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Shares of common stock (in Shares)											225,000
Proceeds amount											$ 18,765

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)						6 Months Ended
	Oct. 31, 2023	Aug. 31, 2023	Jul. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Discontinued Operations [Line Items]
Definitive agreement						$ 750,000
Stub Period Reimbursement					$ 31,381
Gross receipts	$ 1,873,993
Net proceeds	1,186,231
Aggregate merger consideration						1%
Net cash used in operations							$ (49,561)
Gain from disposal of discontinued operations						2,674,069
Other receivables					750,000
PBACO [Member]
Discontinued Operations [Line Items]
Definitive agreement			$ 1,750,000
Net incremental cash consideration			150,000
Net after commissions			120,000	$ 1,180,000
MSSP [Member]
Discontinued Operations [Line Items]
Definitive agreement						3,000,000
AHP Merger Agreement [Member]
Discontinued Operations [Line Items]
Stub Period Reimbursement					$ 31,381
Net incremental cash consideration		$ 1,750,000	1,750,000	1,750,000		500,000	1,750,000
Net after commissions		$ 1,540,000	$ 1,540,000	1,540,000		$ 1,873,993
Transfer milestones rate						100%
Other expenses						$ 1,186,231
AHP Merger Agreement [Member] | PBACO [Member]
Discontinued Operations [Line Items]
Net incremental cash consideration				$ 1,225,000			$ 1,225,000
AHP Merger Agreement [Member] | 2022 MSSP [Member]
Discontinued Operations [Line Items]
Net after commissions	1,873,993
Other expenses	$ 1,186,231

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of Financial Results of the ACO/MSO Division - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue				$ 23,646
Operating Expenses and Costs:
Medicare shared savings expenses		14,452		82,387
Loss from operations of discontinued operations before income taxes		(14,452)		(58,741)
Provision for income taxes
Loss from discontinued operations, net of income taxes		(14,452)		(58,741)
Consulting revenue [Member]
Revenue:
Total revenue				$ 23,646

Discontinued Operations (Deta_3

Discontinued Operations (Details) - Schedule of Fair Value of Consideration Received and Receivable - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Fair Value of Consideration Received and Receivable [Abstract]
Upfront Cash Consideration paid at signing	$ 750,000
Incremental Cash Consideration	1,311,567
IPO Share Consideration	1,463,517
2022 MSSP Consideration	312,987
Physician Advance Consideration	199,645
Stub Period Reimbursement	31,381
Total fair value of contingent consideration receivable	3,319,097
Total fair value of consideration received and receivable	$ 4,069,097	$ (4,069,097)

Discontinued Operations (Deta_4

Discontinued Operations (Details) - Schedule of Assets and Liabilities Derecognized	Jun. 30, 2024 USD ($)
Schedule of Assets and Liabilities Derecognized [Abstract]
Prepaid expenses	$ 1,500
Intangible asset - ACO physician contract	1,073,000
Goodwill	381,856
Contract liability	(20,278)
Contingent acquisition consideration	(185,024)
Net Book Value of Assets and Liabilities Sold	$ 1,251,054

Discontinued Operations (Deta_5

Discontinued Operations (Details) - Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities [Abstract]
Total fair value of consideration received and receivable	$ (4,069,097)	$ 4,069,097
Less: net book value of assets and liabilities sold		(1,251,054)
Less: fair value of Indemnification Clause		(143,974)
Gain from disposal of discontinued operations		$ 2,674,069

Discontinued Operations (Deta_6

Discontinued Operations (Details) - Schedule of Remaining Unresolved Components of Contingent Consideration Receivable	Jun. 30, 2024 USD ($)
Schedule of Remaining Unresolved of Contingent Consideration Receivable [Abstract]
IPO Share Consideration	$ 1,463,518
Physician Advance Consideration	199,645
Remaining contingent sale consideration receivable	$ 1,663,163

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Details) - Schedule of Prepaid and Other Expenses - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Prepaid Expenses and Other [Abstract]
Insurance prepayments	$ 8,099	$ 11,209
Other expense prepayments	18,379	38,391
Rent deposits	50,047	50,547
Contract assets	8,264	5,110
Total prepaid expenses and other	84,789	105,257
Less: long term portion	(50,047)	(50,047)
Prepaid expenses and other, current portion	$ 34,742	$ 55,210

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property and Equipment [Abstract]
Depreciation expense	$ 29,531	$ 31,253	$ 59,000	$ 62,290

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Property, Plant and Equipment [Line Items]
Total property and equipment, Gross	$ 814,415	$ 811,817
Less: accumulated depreciation	(580,062)	(521,062)
Property and equipment, net	234,353	290,755
Medical equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total property and equipment, Gross	496,452	493,854
Furniture, office equipment and leasehold improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total property and equipment, Gross	$ 317,963	$ 317,963

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Intangible Assets [Abstract]
Amortization expense	$ 55,731	$ 57,040	$ 112,771	$ 114,080

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Intangible Assets [Line Items]
Total intangible assets	$ 1,142,538	$ 1,142,538
Less: accumulated amortization	(371,461)	(258,690)
Intangible assets, net	771,077	883,848
NCFM: Medical database [Member]
Schedule of Intangible Assets [Line Items]
Total intangible assets	1,101,538	1,101,538
NCFM: Website [Member]
Schedule of Intangible Assets [Line Items]
Total intangible assets	$ 41,000	$ 41,000

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Future Amortization Expense of Intangible Assets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Future Amortization Expense of Intangible Assets [Abstract]
2024 (July to December)	$ 110,154
2025	220,308
2026	220,308
2027	220,307
Thereafter
Total future amortization expense	$ 771,077	$ 883,848

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Line Items]
Weighted-average remaining lease term to operating leases	2 years 2 months 12 days		2 years 2 months 12 days
Weighted-average discount rate	22.79%		22.79%
Lease expense	$ 129,968	$ 120,501	$ 259,399	$ 227,297

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease-Related Assets and Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Lease-Related Assets and Liabilities [Abstract]
Lease assets	$ 798,593	$ 935,812
Lease liabilities
Lease liabilities (short term)	363,482	326,033
Lease liabilities (long term)	438,555	613,386
Total lease liabilities	$ 802,037	$ 939,419

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Maturities of Operating Lease Liabilities [Abstract]
2024 (July to December)	$ 279,478
2025	477,584
2026	335,634
2027	990
Total lease payments	1,093,686
Less interest	(291,649)
Present value of lease liabilities	$ 802,037	$ 939,419

Accounts Payable, Accrued Exp_3

Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Accounts Payable and Accrued Expenses [Abstract]
Trade accounts payable	$ 527,645	$ 251,479
Accrued payroll liabilities	99,282	110,103
Accrued operating expenses	73,007	91,238
Accrued interest	65,579	57,074
Accrued commissions payable from 2022 MSSP Consideration	25,000	100,000
Contingent acquisition consideration payable	1,479	2,189
Product return allowance	2,354	2,095
Total	$ 794,346	$ 614,178

Contract Liabilities (Details)

Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	$ 284,213	$ 271,774
Patient services paid but not provided - NCFM [Member]
Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	144,966	95,334
Patient services paid but not provided - BTG [Member]
Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	88,256	100,857
Patient services paid but not provided - NWC [Member]
Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	50,029	75,438
Unshipped products - MOD [Member]
Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	$ 962	$ 145

Amounts Due to Related Party _3

Amounts Due to Related Party and Related Party Transactions (Details) - USD ($)																3 Months Ended			6 Months Ended		12 Months Ended	15 Months Ended
	Jun. 03, 2024	Apr. 18, 2024	Apr. 10, 2024	Mar. 27, 2024	Dec. 01, 2023	Nov. 30, 2023	Jun. 08, 2023	Apr. 30, 2023	Apr. 27, 2023	Apr. 13, 2023	Mar. 14, 2023	Feb. 14, 2023	Jan. 13, 2023	Jan. 05, 2023	Dec. 13, 2022	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jun. 30, 2024	Jun. 27, 2024	Mar. 30, 2024	Jun. 26, 2023	Jun. 02, 2023	May 12, 2023	Nov. 08, 2022
Amounts Due to Related Party and Related Party Transactions [Line Items]
Amortization of debt discount																$ 0		$ 4,748	$ 0	$ 0
Exercise price (in Dollars per share)																	$ 0.2
Warrants issued (in Shares)																19,992,346		10,619,698	19,992,346	10,619,698		19,992,346
Loss on extinguishment of debt																$ (73,567)		$ (44,169)	$ (170,227)	$ (88,932)
Net proceeds																			135,000	408,500
Repayments																			$ 510,773	373,948
Common stock at a fixed conversion price (in Dollars per share)	$ 0.0497	$ 0.05	$ 0.0577	$ 0.0573
Warrants to purchase shares (in Shares)				6,660,000												393,750			393,750			393,750
Gain on change in fair value of debt																$ 27,900			$ 27,900
Fair value of embedded BCF	$ 392,905															392,905	$ 146,405
Deferred compensation payable																300,600			300,600		$ 300,600	$ 300,600
Compensation received																0		5,203	0	10,353
March 2024 Warrant [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Fair value of the warrants				$ 254,345
Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable																77,613			77,613		166,487	77,613
Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Loss on extinguishment of debt																		0		3,582
Unsecured Promissory Notes [Member] | March 2024 Warrant [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Exercise price (in Dollars per share)				$ 0.06
Dr. Dent [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest rate														15%
Notes and Convertible Notes Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest accrued																			21,213		7,456
Loan [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest expense net of interest income received																28,597		35,306	24,549	40,196
Other Related Transactions [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Compensation received																			20,000
Dr Dent [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Consulting fees																33,462		22,308	72,500	50,192
Dr Dent [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount														$ 10,000
Discount against note payable														$ 3,851
Amortization of debt discount																		269		269
Exercise price (in Dollars per share)														$ 0.104
Fair value of the warrants														$ 6,843
Face value														$ 10,000
Warrants issued (in Shares)														96,154
Interest expense																		53		53
January 2023 Dent Note [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Amortization of debt discount																				1,373
Interest expense																				397
Loss on extinguishment of debt																				41,181
January 2023 Dent Note [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount													$ 161,000
Discount against note payable													$ 42,553
January 2023 Dent Note [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Exercise price (in Dollars per share)													$ 0.093
Fair value of the warrants													$ 56,123
Face value													$ 161,000
Interest rate													15%
Warrants issued (in Shares)													860,215
Net proceeds													$ 160,000
Original issue discount													$ 1,000
February 2023 Dent Note [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount												$ 186,000
February 2023 Dent Note [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable												$ 50,989
Amortization of debt discount																0		25,494	0	38,241
Exercise price (in Dollars per share)												$ 0.135
Fair value of the warrants												$ 66,136
Face value												$ 186,000
Interest rate												15%
Warrants issued (in Shares)												685,185
Net proceeds												$ 185,000
Original issue discount												$ 1,000
March 2023 Dent Note [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable																26,011			26,011			$ 26,011
Payment amount								$ 12,601
Amortization of debt discount																2,504		7,351	2,504	8,643
March 2023 Dent Note [Member] | Promissory Note [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount											$ 126,011
Discount against note payable											26,011
Payment amount																$ 0		25,202	$ 0	25,202
Net proceeds											100,000
Original issue discount											12,510
Principal amount											112,510
Prepaid interest											13,501
Repayments											$ 126,011
Maturity date											Mar. 14, 2024
Discount rate																15%			15%			15%
April 2023 Dent Note [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable										$ 15,000
Amortization of debt discount																		15,000		15,000
Exercise price (in Dollars per share)																											$ 0.0764
Warrants issued (in Shares)																											654,450
Loss on extinguishment of debt																		31,621		31,621
April 2023 Dent Note [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Face value										100,000
Net proceeds										$ 100,000
Maturity date										May 12, 2023
Fixed interest										$ 15,000
Fixed interest rate										15%
April 2023 O’Leary Note [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Amortization of debt discount																		5,250		5,250
Loss on extinguishment of debt																		12,549		12,549
April 2023 O’Leary Note [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable									$ 5,250
Exercise price (in Dollars per share)																										$ 0.067
Face value									35,000
Warrants issued (in Shares)																										261,194
Net proceeds									35,000
Fixed interest									$ 5,250
Fixed interest rate									15%
June 2023 Dent Note I [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable							$ 4,500
June 2023 Dent Note I [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Amortization of debt discount																		4,500		4,500
Face value							30,000
Net proceeds							30,000
Fixed interest							$ 4,500
Fixed interest rate							15%
June 2023 Dent Note II [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Amortization of debt discount																$ 0			$ 0	41		$ 41
June 2023 Dent Note II [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount																									$ 26,875
Discount against note payable																									1,875
Face value																									25,000
Fixed interest																									$ 1,875
Fixed interest rate																									15%
December Two Thousand Twenty Three Dent Note [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount					$ 166,500
Discount against note payable					$ 48,769
Payment amount																0		0	32,330	0
Exercise price (in Dollars per share)					$ 0.06
Face value					$ 150,000
Warrants issued (in Shares)					1,500,000
Net proceeds					$ 150,000
Maturity date					Feb. 28, 2024
Fixed interest					$ 15,000
Fixed interest rate					10%
Fixed fees					$ 1,500
Fair value warrants					$ 32,269
March 2024 Dent Note II [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable																203,588			203,588			203,588
Amortization of debt discount																194,736		0	203,588	0
Loss on extinguishment of debt																65,936			65,936
Principal amount				$ 150,000
Net proceeds																			350,000
Fair value of note																								$ 405,006
Gain on change in fair value of debt																12,273			12,273
Carrying value																392,733			392,733			392,733
March 2024 Dent Note II [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest rate				12%
Principal amount				$ 350,000
March 2024 Dent Note II [Member] | Unsecured Promissory Notes [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Exercise price (in Dollars per share)																							$ 0.081
March 2024 Dent Note II [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable																89,222			89,222			89,222
Amortization of debt discount																54,128		0	56,508	0
Net proceeds																			150,000
Carrying value																117,285			117,285		0	117,285
Remaining principal payments																150,000			150,000		0	150,000
March 2024 Dent Note II [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest rate				12%
Principal amount				$ 166,500
Maturity date				Aug. 24, 2024
March 2024 Dent Note III [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Fair value of the warrants																			33,121
Loss on extinguishment of debt																0			96,660
Principal amount																			166,500
Gain on change in fair value of debt																15,627			15,627
Carrying value																183,994			183,994			$ 183,994
March 2024 Dent Note III [Member] | March 2024 Warrant [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Fair value of the warrants																			63,539
March 2024 Dent Note III [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest rate				12%
Maturity date				Aug. 28, 2024
April 2023 Dent Note I [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount			$ 150,000
Interest rate			12%
Net proceeds			$ 150,000
April 2023 Dent Note I [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Principal amount			$ 150,000
April 2023 Dent Note II [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount		$ 50,000
Net proceeds		$ 50,000
April 2023 Dent Note II [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest rate		12%
Principal amount		$ 50,000
June 2024 Dent Note [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Note payable amount	$ 1,000,000
Amortization of debt discount																58,128		0	58,128	0
Exercise price (in Dollars per share)	$ 0.0497
Face value	$ 333,111
Warrants issued (in Shares)	785,811
Net proceeds	$ 950,000
June 2024 Dent Note [Member] | Warrant [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Warrants issued (in Shares)	10,000,000
June 2024 Dent Note [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Interest rate	12%
Principal amount	$ 1,000,000
November Merchant Cash Advance Factoring Agreement [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Advance received																												$ 150,000
Loan repayment						$ 3,750
Repaid amount						$ 195,000
Note payable amount																												195,000
Amortization of debt discount																0		11,219	0	22,438
November Merchant Cash Advance Factoring Agreement [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable																												$ 45,000
Payment amount																0		67,500	0	101,250
December Merchant Cash Advance Factoring Agreement [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Advance received															$ 110,000
Loan repayment																					2,750
Repaid amount																					$ 143,000
Note payable amount															$ 143,000
Amortization of debt discount																0		17,071	0	34,141
Warrants issued (in Shares)															3,142,857
Exercise price (in Dollars per share)															$ 0.035
Fair value of the warrants															$ 63,420
December Merchant Cash Advance Factoring Agreement [Member] | Note Payable [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Discount against note payable															$ 68,281
Payment amount																$ 0		$ 49,500	$ 0	$ 74,250
Director [Member]
Amounts Due to Related Party and Related Party Transactions [Line Items]
Shares issuable (in Shares)																			1,224,492		408,164

Amounts Due to Related Party _4

Amounts Due to Related Party and Related Party Transactions (Details) - Schedule of Amounts Due to Related Parties - Due to Related Party [Member] - USD ($)		Jun. 30, 2024	Dec. 31, 2023
Schedule of Amounts Due to Related Parties [Line Items]
Face value of notes payable to related party		$ 1,926,727	$ 205,976
Less: unamortized discounts		(760,397)	(34,834)
Notes payable to related party, total		1,166,330	171,142
Plus deferred compensation payable to Dr. Michael Dent		300,600	300,600
Total due to related party		1,466,930	471,742
Note Payable, March 2023 [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Note Payable			12,601
Note Payable, June 2023 [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Note Payable			26,875
Note Payable, December 2023 [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Note Payable			166,500
Convertible Note Payable I [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable		150,000
Convertible Note Payable II [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable	[1]	392,733
Convertible Note Payable III [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable	[1]	183,994
Convertible Note Payable IV [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable		150,000
Convertible Note Payable V [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable		50,000
Convertible Note Payable VI [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable		$ 1,000,000
[1]- denotes note payable carried at fair value

Notes Payable (Details)

Notes Payable (Details) - USD ($)														3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 03, 2024	Apr. 22, 2024	Apr. 18, 2024	Apr. 10, 2024	Mar. 27, 2024	Dec. 13, 2023	Dec. 12, 2023	Nov. 03, 2023	Aug. 08, 2023	Mar. 10, 2023	Nov. 04, 2022	Oct. 21, 2022	Jul. 19, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Apr. 30, 2023	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020
Notes Payable [Line Items]
Disaster relief loans														$ 450,000		$ 450,000		$ 450,000
Interest accrued														65,579		65,579		57,074
Interest income																13,158	$ 14,951
Remaining principal payments																450,000		450,000
Net Carrying amount														450,000		450,000		450,000
Accrued interest													5%
Net proceeds							$ 125,000
Payment premium percentage													2%
Amortization expense discount														0	$ 4,748	0	0
Outstanding amount
Conversion price per share (in Dollars per share)	$ 0.0497		$ 0.05	$ 0.0577	$ 0.0573
SBA Loans [Member]
Notes Payable [Line Items]
Interest accrued														22,376		22,376		27,628
Interest expense (income)														1,860	11,001	7,906	6,783
Loan [Member]
Notes Payable [Line Items]
Interest expense (income)														28,597	35,306	24,549	40,196
Interest income														6,579	9,834
Accrues Interest [Member]
Notes Payable [Line Items]
Interest rate, percentage													0%
Maturity date													Jan. 19, 2023
Net proceeds													$ 522,500
Total cash repayments													561,000
Discount against note													38,500
Proceeds of sales																18,765
October 2022 Note [Member]
Notes Payable [Line Items]
Principal amount												$ 144,760
Maturity date												Oct. 31, 2023
Net proceeds												$ 125,000
Discount against note												37,131
Original issue discount												15,510
Other fees												4,250
Monthly payments												$ 16,213
AEU Notes Payable [Member]
Notes Payable [Line Items]
Net proceeds											$ 35,800
Amortization expense discount														0	1,621	0	3,988
Outstanding amount														0	12,762	0	31,393
Gross amount											41,009
Recognized discount amount											$ 5,209
March 2023 Note Payable [Member]
Notes Payable [Line Items]
Principal amount										$ 116,760
Maturity date										Mar. 10, 2024
Net proceeds										$ 100,000
Discount against note																30,771
Amortization expense discount														0	8,696	0	10,225
Outstanding amount														0	26,154	0	26,154
Original issue discount										12,510
Other fees										4,250
Monthly payments																			$ 13,077
Prepaid interest										14,011
Total repayments										$ 130,771
Note payable August 2023 [Member]
Notes Payable [Line Items]
Principal amount									$ 144,760
Maturity date								Sep. 03, 2024	Jun. 30, 2024
Net proceeds									$ 125,000
Amortization expense discount														10,365	0	13,098	0
Outstanding amount														64,852	0	97,279	0
Original issue discount									15,510
Other fees									4,250
Monthly payments														16,213		16,213
Prepaid interest									17,371
Total repayments									$ 162,131
Extinguishment of debt														7,631		7,631
Discount [Member]
Notes Payable [Line Items]
Discount against note																37,131
November 2023 Note [Member]
Notes Payable [Line Items]
Net Carrying amount														100,400		100,400		253,000
Principal amount								$ 350,000
Net proceeds								317,000
Total cash repayments								378,000
Discount against note								$ 61,000
Amortization expense discount														18,200	0	36,400	0
Outstanding amount														113,400	0	189,000	0
Interest rate, percentage								0%
Original issue discount, percentage								8%
Repaid cash premium, percentage								8%
Remaining principal payments														113,400		113,400		302,400
December 2023 Note I Notes Payable [Member]
Notes Payable [Line Items]
Net Carrying amount														50,769		50,769		127,291
Principal amount							144,760
Net proceeds							37,131
Amortization expense discount														10,971	0	21,941	0
Outstanding amount														49,813	0	98,462	0
Original issue discount							15,510
Other fees							4,250
Monthly payments							16,213
Prepaid interest							17,371
Total repayments							$ 162,131
Remaining principal payments														63,669		63,669		162,131
Conversion right discount, percentage							15%
Notes Payable September 2023 [Member]
Notes Payable [Line Items]
Principal amount						$ 175,000
December 2023 Note II Notes Payable [Member]
Notes Payable [Line Items]
Net Carrying amount														64,811		64,811		127,483
Net proceeds						156,000
Total cash repayments						189,000
Discount against note						$ 66,000
Amortization expense discount														22,664	0	45,328	0
Outstanding amount														81,000	0	108,000	0
Interest rate, percentage						0%
Original issue discount, percentage						8%
Repaid cash premium, percentage						8%
Conversion price per share (in Dollars per share)						$ 0.05
Remaining payments																		189,000
Notes Payable April 2024 Note [Member]
Notes Payable [Line Items]
Net Carrying amount														126,763		126,763		0
Principal amount		$ 161,000
Maturity date		Feb. 28, 2025
Net proceeds		$ 118,787
Amortization expense discount														9,795	0	9,795	0
Outstanding amount														18,032	0	18,032	0
Original issue discount		21,000
Other fees		5,000
Prepaid interest		19,320
Total repayments		$ 180,320
Remaining principal payments														162,288		162,288		$ 0
Conversion right discount, percentage		15%
Investor amount		$ 16,213
Interest payments		$ 18,032
October 2022 Note [Member]
Notes Payable [Line Items]
Amortization expense discount														0	10,865	0	21,610
Outstanding amount														0	$ 48,639	0	81,066
Yorkville [Member]
Notes Payable [Line Items]
Principal amount													$ 550,000
Yorkville [Member] | December 2023 Note II Notes Payable [Member]
Notes Payable [Line Items]
Remaining payments														$ 81,000		81,000
Subsidiaries [Member]
Notes Payable [Line Items]
Disaster relief loans																				$ 450,000	$ 450,000	$ 450,000
Percentage of loans bear interest																				3.75%	3.75%	3.75%
Maturity term																				30 years	30 years	30 years
Other Notes Payable [Member]
Notes Payable [Line Items]
Outstanding amount																$ 0
Other Notes Payable [Member] | Accrues Interest [Member]
Notes Payable [Line Items]
Outstanding amount																	$ 168,300

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of Notes Payable - Note Payable [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Notes Payable [Line Items]
Face value of notes payable	$ 870,356	$ 1,200,810
Less: unamortized discounts	(77,613)	(166,487)
Notes payable, total	792,743	1,034,323
Less: long term portion	(450,000)	(450,000)
Notes payable, current portion	342,743	584,323
SBA Disaster Relief Loans [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	450,000	450,000
1800 Diagonal Note Payable III, August 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable		97,279
Yorkville Note Payable III, November 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	113,400	302,400
1800 Diagonal Note Payable III, December 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	63,669	162,131
Yorkville Note Payable III, December 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	81,000	189,000
1800 Diagonal Note Payable IV, April 2024 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	$ 162,287

Shareholders' Equity (Deficit_2

Shareholders' Equity (Deficit) (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 05, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	Jul. 11, 2022	Sep. 09, 2021	Jan. 01, 2016
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)		281,947,151		281,947,151			275,964,958
Common stock par value (in Dollars per share)		$ 0.0001		$ 0.0001			$ 0.0001
Aggregate daily volume percentage	30%
Purchase percentage	96%
Shares of common stock underlying (in Shares)								30,000,000
Proceeds for the issuance of common stock				$ 405,000	$ 475,000
Sale of shares (in Shares)	30,000,000		5,416,667		7,416,667
Proceeds from sales		$ 275,000		$ 475,000
Warrants to purchase of common stock (in Shares)						1,500,000
Exercise price (in Dollars per share)						$ 0.2
Weighted average grant date fair value of share grants (in Dollars per share)				$ 0.0569	$ 0.09
Issued warrants (in Shares)		19,992,346	10,619,698	19,992,346	10,619,698
Aggregate grant date fair value		$ 754,657	$ 510,235	$ 754,657	$ 510,235
Total unrecognized compensation cost		8,653		$ 8,653
Weighted-average period				1 year 2 months 12 days
Aggregate grant fair value		40,588	52,756	$ 40,588	52,756
Amortization of deferred stock compensation		$ 0	5,203	$ 0	10,353
Warrant [Member]
Shareholder’s Equity [Line Items]
Warrants to purchase of common stock (in Shares)		1,562,500		1,562,500
Stock Option [Member]
Shareholder’s Equity [Line Items]
Stock based compensation expense		$ 15,616	15,238	$ 63,515	37,748
Minimum [Member]
Shareholder’s Equity [Line Items]
Exercise price (in Dollars per share)		$ 0.15		$ 0.15
Maximum [Member]
Shareholder’s Equity [Line Items]
Exercise price (in Dollars per share)		$ 0.16		$ 0.16
2021 EIP [Member]
Shareholder’s Equity [Line Items]
Issuance of common stock (in Shares)									20,000,000
Employee Equity Incentives Plans [Member]
Shareholder’s Equity [Line Items]
Total unrecognized compensation cost		$ 79,525		$ 79,525
Weighted-average period				1 year 4 months 24 days
Fair value of options vested				$ 147,568	35,954
Stock based compensation expense		$ 87,035	76,402	$ 123,021	$ 159,353
Common Stock [Member]
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)	2,000,000
Common stock par value (in Dollars per share)	$ 0.0001
Issuance shares of common stock (in Shares)					225,000
Warrants to purchase of common stock (in Shares)		5,000,000		5,000,000
Exercise price (in Dollars per share)		$ 0.05		$ 0.05
Stock Option [Member]
Shareholder’s Equity [Line Items]
Fair value options granted (in Dollars per share)				$ 0.04	$ 0.05
Stock Based Compensation [Member]
Shareholder’s Equity [Line Items]
Stock based compensation expense		$ 1,796	$ 24,172	$ 3,592	$ 49,640
SEPA [Member]
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)	30,000,000
SEPA [Member] | Common Stock [Member]
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)	30,000,000
Common stock par value (in Dollars per share)	$ 0.0001
Proceeds for the issuance of common stock					$ 18,765
Consultants [Member] | Common Stock [Member]
Shareholder’s Equity [Line Items]
Purchase of shares (in Shares)				2,504,974
Yorkville [Member]
Shareholder’s Equity [Line Items]
Owning percentage	4.99%
Common Stock [Member] | 2016 EIP [Member]
Shareholder’s Equity [Line Items]
Issuance of common stock (in Shares)										15,503,680
Private Placement [Member]
Shareholder’s Equity [Line Items]
Sale of shares (in Shares)		877,193		5,977,193
Proceeds from sales		$ 50,000		$ 405,000
Warrants to purchase of common stock (in Shares)		438,596		438,596		2,500,000
Exercise price (in Dollars per share)		$ 0.16		$ 0.16		$ 0.17

Shareholders' Equity (Deficit_3

Shareholders' Equity (Deficit) (Details) - Schedule of Company Obligated to Issue Shares - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Schedule of Company Obligated to Issue Shares [Line Items]
Shares issuable to employees and consultants	$ 110,874	$ 281,682
Shares issuable to independent directors	1,977,143	2,764,352
Shares Issuable to Employees and Consultants [Member]
Schedule of Company Obligated to Issue Shares [Line Items]
Shares issuable to employees and consultants	$ 50,874	$ 261,682
Shares issuable to independent directors	752,651	2,356,188
Shares Issuable to Independent Directors [Member]
Schedule of Company Obligated to Issue Shares [Line Items]
Shares issuable to employees and consultants	$ 60,000	$ 20,000
Shares issuable to independent directors	1,224,492	408,164

Shareholders' Equity (Deficit_4

Shareholders' Equity (Deficit) (Details) - Schedule of Stock Warrants - Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Stock Warrants [Line Items]
Number,Outstanding at beginning of the period	77,414,648	68,109,094
Weighted Average Exercise Price,Outstanding at beginning of the period	$ 0.2	$ 0.22
Number, Outstanding at end of the period	96,064,592	75,066,459
Weighted Average Exercise Price, Outstanding at end of the period	$ 0.18	$ 0.21
Number, Options Exercisable at end of the period	96,064,592	75,066,459
Weighted Average Exercise Price, Options Exercisable at end of the period	$ 0.18	$ 0.21
Weighted average remaining life	3 years 3 months 18 days	2 years 2 months 12 days
Weighted average remaining life
Number, Granted during the period	19,992,346	10,619,698
Weighted Average Exercise Price, Granted during the period	$ 0.07	$ 0.1
Number of Exercised during the period
Weighted Average Exercise Price, Exercised during the period
Number, Expired during the period	(1,342,402)	(3,662,333)
Weighted Average Exercise Price, Expired during the period	$ (0.28)	$ (0.25)

Shareholders' Equity (Deficit_5

Shareholders' Equity (Deficit) (Details) - Schedule of Financial Statements with Respect to the EIPs - Warrant [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
0.0001 to 0.09 [Member]
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Warrants Outstanding, Exercise Prices Lower	$ 0.0001
Warrants Outstanding, Exercise Prices Upper	$ 0.09
Warrants Outstanding, Number Outstanding (in Shares) | shares	40,362,039,000,000
Warrants Outstanding, Weighted-Average Remaining Contractual Life (years)	5 years
Warrants Outstanding, Weighted-Average Exercise Price	$ 0.06
Warrants Exercisable, Number Exercisable (in Shares) | shares	40,362,039
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.06
0.10 to 0.24 [Member]
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Warrants Outstanding, Exercise Prices Lower	0.1
Warrants Outstanding, Exercise Prices Upper	$ 0.24
Warrants Outstanding, Number Outstanding (in Shares) | shares	25,875,536,000,000
Warrants Outstanding, Weighted-Average Remaining Contractual Life (years)	2 years 9 months 18 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 0.16
Warrants Exercisable, Number Exercisable (in Shares) | shares	25,875,536
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.16
0.25 to 0.49 [Member]
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Warrants Outstanding, Exercise Prices Lower	0.25
Warrants Outstanding, Exercise Prices Upper	$ 0.49
Warrants Outstanding, Number Outstanding (in Shares) | shares	26,867,093,000,000
Warrants Outstanding, Weighted-Average Remaining Contractual Life (years)	1 year 3 months 18 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 0.31
Warrants Exercisable, Number Exercisable (in Shares) | shares	26,867,093
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.31
0.50 to 1.05 [Member]
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Warrants Outstanding, Exercise Prices Lower	0.5
Warrants Outstanding, Exercise Prices Upper	$ 1.05
Warrants Outstanding, Number Outstanding (in Shares) | shares	2,959,924,000,000
Warrants Outstanding, Weighted-Average Remaining Contractual Life (years)	2 years
Warrants Outstanding, Weighted-Average Exercise Price	$ 0.68
Warrants Exercisable, Number Exercisable (in Shares) | shares	2,959,924
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.68
0.05 to 1.00 [Member]
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Warrants Outstanding, Exercise Prices Lower	0.05
Warrants Outstanding, Exercise Prices Upper	$ 1
Warrants Outstanding, Number Outstanding (in Shares) | shares	96,064,592,000,000
Warrants Outstanding, Weighted-Average Remaining Contractual Life (years)	3 years 3 months 18 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 0.18
Warrants Exercisable, Number Exercisable (in Shares) | shares	96,064,592
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.18

Shareholders' Equity (Deficit_6

Shareholders' Equity (Deficit) (Details) - Schedule of Aggregate Grant Date Fair Value Warrants	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Pricing model utilized	Binomial Lattice	Binomial Lattice
Risk free rate range [Member] | Minimum [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	3.97	3.6
Risk free rate range [Member] | Maximum [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	4.2	4.27
Expected life range [Member] | Minimum [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	5	0.28
Expected life range [Member] | Maximum [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	10	5
Volatility range [Member] | Minimum [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	139.73	126.3
Volatility range [Member] | Maximum [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	173.25	141.2
Dividend yield [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected forfeiture [Member]
Schedule of Aggregate Grant Date Fair Value Warrants [Line Items]
Warrants and rights outstanding, measurement input	33	20

Shareholders' Equity (Deficit_7

Shareholders' Equity (Deficit) (Details) - Schedule of Financial Statements with Respect to the EIPs - Employee Equity Incentives Plans [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Total cost of share-based payment plans during the period	$ 87,035	$ 76,402	$ 123,021	$ 159,353
Amounts capitalized in deferred equity compensation during period
Amounts written off from deferred equity compensation during period			57,147
Amounts charged against income for amounts previously capitalized		5,204		10,354
Amounts charged against income, before income tax benefit	87,035	81,606	180,168	169,707
Amount of related income tax benefit recognized in income

Shareholders' Equity (Deficit_8

Shareholders' Equity (Deficit) (Details) - Schedule of Stock Option Activity - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Stock Option Activity [Abstract]
Number, Outstanding at beginning of period	5,093,738	5,222,982
Weighted Average Exercise Price, Outstanding at beginning of period	$ 0.16	$ 0.2
Number, Granted during the period	4,804,974	93,750
Weighted Average Exercise Price, Granted during the period	$ 0.06	$ 0.08
Number, Exercised during the period
Weighted Average Exercise Price, Exercised during the period
Number, Forfeited during the period	(449,982)	(450,000)
Weighted Average Exercise Price, Forfeited during the period	$ (0.21)	$ (0.16)
Number, Outstanding at end of period	9,448,730	4,866,732
Weighted Average, Outstanding at end of period	$ 0.1	$ 0.17
Number, Options exercisable at period-end	7,202,896	3,110,815
Weighted Average Exercise Price, Options exercisable at period-end	$ 0.11	$ 0.2

Shareholders' Equity (Deficit_9

Shareholders' Equity (Deficit) (Details) - Schedule of Fair Value of Options Granted	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Fair Value of Options Granted [Line Items]
Pricing model utilized	Binomial Lattice	Binomial Lattice
Risk free rate range	4.20%	3.48%
Expected life range (in years)	10 years	10 years
Volatility range		145.03%
Dividend yield	0%	0%
Expected forfeiture	30%	30%
Minimum [Member]
Schedule of Fair Value of Options Granted [Line Items]
Volatility range	173.09%
Maximum [Member]
Schedule of Fair Value of Options Granted [Line Items]
Volatility range	173.25%

Shareholders' Equity (Defici_10

Shareholders' Equity (Deficit) (Details) - Schedule of Non-Vested Options Issued - Stock Options [Member] - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Non-Vested Options Issued [Line Items]
Shares, Nonvested at beginning of period	1,073,084	2,260,417
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.06	$ 0.08
Shares, Granted	4,804,974	93,750
Weighted Average Grant Date Fair Value, Granted	$ 0.04	$ 0.05
Shares, Vested	(3,582,224)	(298,250)
Weighted Average Grant Date Fair Value, Vested	$ (0.04)	$ (0.12)
Shares, Forfeited	(50,000)	(300,000)
Weighted Average Grant Date Fair Value, Forfeited	$ (0.08)	$ (0.09)
Shares, Nonvested at end of period	2,245,834	1,755,917
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.05	$ 0.07

Shareholders' Equity (Defici_11

Shareholders' Equity (Deficit) (Details) - Schedule of Stock Grant Activity - Stock Grants [Member] - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Stock Grant Activity [Line Items]
Shares, Nonvested at beginning of period	1,484,488	1,651,435
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.05	$ 0.05
Shares, Granted		160,944
Weighted Average Grant Date Fair Value, Granted		$ 0.09
Shares, Vested	(821,328)	(981,584)
Weighted Average Grant Date Fair Value, Vested	$ (0.05)	$ (0.05)
Shares, Forfeited	(50,000)	(15,000)
Weighted Average Grant Date Fair Value, Forfeited	$ (0.12)	$ (0.26)
Shares, Nonvested at end of period	613,160	815,795
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.05	$ 0.05

Commitments and Contingencies_2

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Supplier Concentration Risk [Member] | Product Sales [Member] | Single Supplier [Member]
Commitments and Contingencies [Line Items]
Concentration risk, percentage	94%	91%

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Maturities of Operating Lease Liabilities [Abstract]
2024 (July to December)	$ 279,478
2025	477,584
2026	335,634
2027	990
Total lease payments	1,093,686
Less interest	(291,649)
Present value of lease liabilities	$ 802,037	$ 939,419

Segment Reporting (Details)

Segment Reporting (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Segment Reporting [Line Items]
Number of reportable segments			3
Digital Healthcare Division [Member]
Segment Reporting [Line Items]
Intercompany sales	$ 336	$ 120	$ 516	$ 300
Medical Distribution Segment [Member]
Segment Reporting [Line Items]
Intercompany sales	$ 0	$ 5,013	$ 0	$ 13,353

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Segment Information - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Revenue
Total revenue	$ 795,078	$ 1,703,496	$ 1,799,310	$ 3,458,650
Operating Expenses
Practice salaries and benefits	513,891	898,992	1,097,047	1,862,649
Other practice operating expenses	389,222	646,216	871,805	1,270,463
Cost of product revenue	24,723	34,397	55,302	66,457
Selling, general and administrative expenses	861,469	833,689	1,860,912	1,937,437
Depreciation and amortization	85,262	88,293	171,771	176,370
Total Operating Expenses	1,874,567	2,501,587	4,056,837	5,313,376
Income (loss) from operations	(1,079,489)	(798,091)	(2,257,527)	(1,854,726)
Other Segment Information
Loss on extinguishment of debt	73,567	44,169	170,227	88,932
Change in fair value of debt	(27,900)		(27,900)
Amortization of original issue discounts on notes payable	371,356	128,689	479,621	192,049
Gain from realization of contingent sale consideration receivable		(15,000)		15,000
Change in fair value of contingent acquisition consideration	(635)	(6,070)	(711)	(4,364)
Interest expense (income)	44,559	39,124	49,390	50,505
Identifiable Assets
Identifiable assets	3,859,664	5,205,158	3,859,664	5,205,158	$ 4,280,140
Goodwill		319,958		319,958
Patent service revenue, net [Member]
Revenue
Total revenue	763,163	1,630,334	1,726,784	3,330,615
Subscription revenue [Member]
Revenue
Total revenue	8,166	19,177	15,794	35,476
Product revenue [Member]
Revenue
Total revenue	23,749	53,985	56,732	92,559
Product and other revenue [Member]
Revenue
Total revenue			56,732	92,559
Health Services [Member]
Revenue
Total revenue	763,163	1,630,334	1,726,784	3,330,615
Operating Expenses
Practice salaries and benefits	513,891	898,992	1,097,047	1,862,649
Other practice operating expenses	389,222	646,216	871,805	1,270,463
Cost of product revenue
Selling, general and administrative expenses
Depreciation and amortization	83,922	86,887	169,091	173,559
Total Operating Expenses	987,035	1,632,095	2,137,943	3,306,671
Income (loss) from operations	(223,872)	(1,761)	(411,159)	23,944
Other Segment Information
Loss on extinguishment of debt
Change in fair value of debt
Amortization of original issue discounts on notes payable				3,988
Gain from realization of contingent sale consideration receivable
Change in fair value of contingent acquisition consideration
Interest expense (income)	4,567	4,191	5,517	7,003
Identifiable Assets
Identifiable assets	1,554,359	2,061,059	1,554,359	2,061,059	1,812,609
Goodwill		319,958		319,958
Health Services [Member] | Patent service revenue, net [Member]
Revenue
Total revenue	763,163	1,630,334	1,726,784	3,330,615
Health Services [Member] | Subscription revenue [Member]
Revenue
Total revenue
Health Services [Member] | Product revenue [Member]
Revenue
Total revenue
Health Services [Member] | Product and other revenue [Member]
Revenue
Total revenue
Digital Healthcare [Member]
Revenue
Total revenue	8,166	19,177	15,794	35,476
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Cost of product revenue
Selling, general and administrative expenses	842,524	803,012	1,822,698	1,873,333
Depreciation and amortization	1,340	1,406	2,680	2,811
Total Operating Expenses	843,864	804,418	1,825,378	1,876,144
Income (loss) from operations	(835,698)	(785,241)	(1,809,584)	(1,840,668)
Other Segment Information
Loss on extinguishment of debt	73,567	44,169	170,227	88,932
Change in fair value of debt	(27,900)		(27,900)
Amortization of original issue discounts on notes payable	371,356	128,689	479,621	188,061
Gain from realization of contingent sale consideration receivable		(15,000)		15,000
Change in fair value of contingent acquisition consideration	(635)	(6,070)	(711)	(4,364)
Interest expense (income)	39,992	34,933	43,873	43,502
Identifiable Assets
Identifiable assets	2,285,209	3,121,024	2,285,209	3,121,024	2,457,849
Goodwill
Digital Healthcare [Member] | Patent service revenue, net [Member]
Revenue
Total revenue
Digital Healthcare [Member] | Subscription revenue [Member]
Revenue
Total revenue	8,166	19,177	15,794	35,476
Digital Healthcare [Member] | Product revenue [Member]
Revenue
Total revenue
Digital Healthcare [Member] | Product and other revenue [Member]
Revenue
Total revenue
Medical Distribution {[Member]
Revenue
Total revenue	23,749	53,985	56,732	92,559
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Cost of product revenue	24,723	34,397	55,302	66,457
Selling, general and administrative expenses	18,945	30,677	38,214	64,104
Depreciation and amortization
Total Operating Expenses	43,668	65,074	93,516	130,561
Income (loss) from operations	(19,919)	(11,089)	(36,784)	(38,002)
Other Segment Information
Loss on extinguishment of debt
Change in fair value of debt
Amortization of original issue discounts on notes payable
Gain from realization of contingent sale consideration receivable
Change in fair value of contingent acquisition consideration
Interest expense (income)
Identifiable Assets
Identifiable assets	20,096	23,075	20,096	23,075	$ 9,682
Goodwill
Medical Distribution {[Member] | Patent service revenue, net [Member]
Revenue
Total revenue
Medical Distribution {[Member] | Subscription revenue [Member]
Revenue
Total revenue
Medical Distribution {[Member] | Product revenue [Member]
Revenue
Total revenue	$ 23,749	$ 53,985
Medical Distribution {[Member] | Product and other revenue [Member]
Revenue
Total revenue			$ 56,732	$ 92,559

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Schedule of Fair Value Measurements - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Assets:
Contingent sale consideration receivable	$ 1,663,163	$ 1,663,163
Liabilities:
Contingent acquisition consideration payable	1,479	2,189
Convertible notes payable to related party	576,727
Total liabilities	578,206	2,189
Level 1 [Member]
Assets:
Contingent sale consideration receivable
Liabilities:
Contingent acquisition consideration payable
Convertible notes payable to related party
Total liabilities
Level 2 [Member]
Assets:
Contingent sale consideration receivable
Liabilities:
Contingent acquisition consideration payable
Convertible notes payable to related party
Total liabilities
Level 3 [Member]
Assets:
Contingent sale consideration receivable	1,663,163	1,663,163
Liabilities:
Contingent acquisition consideration payable	1,479	2,189
Convertible notes payable to related party	576,727
Total liabilities	$ 578,206	$ 2,189

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Details) - Schedule of Gains (Losses) from the Change in Fair Value of Level 3 Financial Instruments - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Gains (Losses) from the Change in Fair Value of Level 3 Financial Instruments [Abstract]
Change in fair value of debt	$ 27,900		$ 27,900
Contingent acquisition consideration payable	635	6,070	711	4,364
Total	$ 28,535	$ 6,070	$ 28,611	$ 4,364

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Aug. 01, 2024	Jul. 31, 2024
Subsequent Events [Line Items]
Net proceeds	$ 200,000
Repayments of borrowing	$ 223,649
Dr. Michael Dent [Member]
Subsequent Events [Line Items]
Notes payable		$ 235,000